The QualityStocks Daily Thursday, May 5th, 2022

Today's Top 3 Investment Newsletters

MarketClub Analysis(NLST) $5.3600 +30.73%

QualityStocks(CYN) $3.7400 +17.98%

Kiplinger Today(ALB) $236.5000 +9.76%

The QualityStocks Daily Stock List

Kingstone Companies, Inc. (KINS)

StreetInsider, MarketBeat, Zacks, Trading Concepts, The Street Report, StocksEarning, Short Term Wealth, QualityStocks, Investors Alley and InvestorPlace reported earlier on Kingstone Companies, Inc. (KINS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Kingstone Companies, Inc. is a Northeast regional property and casualty insurance holding company. It is the parent of Kingstone Insurance Company (KICO). KICO is a foremost provider of insurance products for individuals and landlords. KICO writes business solely via licensed agents and brokers, and never direct to consumer.

Kingstone Companies previously went by the name DCAP Group, Inc. It changed its name to Kingstone Companies, Inc. in July of 2009. Established in 1886 and NasdaqCM-listed, Kingstone Companies has its head office in Kingston, New York. The Company also has a second office in Valley Stream, New York.

Kingstone currently operates in New York, New Jersey, Rhode Island, Massachusetts, and Connecticut. In addition, Kingstone is licensed in Pennsylvania, New Hampshire, as well as Maine.

Kingstone offers personal lines insurance products, including homeowners and dwelling fire multi-peril, cooperative/condominiums, renters, and personal umbrella policies. In addition, the Company provides commercial liability policies, including business owners policies consisting mainly of small business retail, service, and office risks; artisan's liability policies for small independent contractors; multi-peril policies for larger and specialized risks, and business owners risks; and commercial umbrella policies.

Furthermore, it offers for-hire vehicle physical damage only policies for livery and car service vehicles and taxicabs; and canine legal liability policies. Moreover, the Company offers reinsurance products.

Kingstone Companies, Inc. (KINS), closed Thursday's trading session at $4.83, up 16.9492%, on 98,551 volume. The average volume for the last 3 months is 98,537 and the stock's 52-week low/high is $3.95/$8.73.

Brainstorm Cell Therapeutics (BCLI)

Streetwise Reports, QualityStocks, Wall Street Resources, MarketBeat, StockMarketWatch, MarketClub Analysis, AllPennyStocks, FeedBlitz, StreetInsider, The Street, TraderPower, Emerging Markets, INO.com Market Report, OTCPicks, Penny Invest, BUYINS.NET, Pumps and Dumps, StockEgg, StockMister, BullRally, Trades Of The Day, CoolPennyStocks, TradersPro, FreeRealTime, HotOTC, PennyStocks24, Stock Stars, SmallCap Network, Marketbeat.com, Stock Rich, OTC Advisors, Stock Fortune Teller, Stock Beast, SmallCapVoice, SmallCap Sentinel and IRGnews Alert reported earlier on Brainstorm Cell Therapeutics (BCLI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) (FRA: GHDN) is a biotechnology firm that is focused on developing and commercializing autologous cell therapies to treat neurodegenerative ailments.

The firm has its headquarters in New York and was incorporated in 2000, on September 22nd. Prior to its name change in November 2004, the firm was known as Golden Hand Resources Inc. It operates as part of the pharmaceutical and medicine manufacturing industry, under the health care sector. The firm has two companies in its corporate family and serves consumers in the United States.

The company is dedicated to defeating neurodegenerative illnesses using its innovative technology platform dubbed NurOwn. It is party to a partnership agreement with Catalent, which entails the manufacture of NurOwn, which has been designed to develop new adult stem cell therapies for various indications.

The enterprise is involved in the development of NurOwn, which is in phase 2 clinical trials evaluating its effectiveness in treating Alzheimer’s disease and progressive multiple sclerosis. This technology has also concluded phase 3 clinical trials testing its efficacy in treating amyotrophic lateral sclerosis, which is a progressive nervous system illness that affects nerve cells in the spinal cord and brain, leading to a loss in muscle control.

The firm is focused on advancing its NurOwn technology, which it holds the right to develop and commercialize. This is in addition to positioning itself for sustained success by addressing the urgent unmet needs of patients with amyotrophic lateral sclerosis and providing broad patient access once its technology is approved.

Brainstorm Cell Therapeutics (BCLI), closed Thursday's trading session at $3.26, up 9.0301%, on 253,140 volume. The average volume for the last 3 months is 252,666 and the stock's 52-week low/high is $2.75/$4.46.

Better Therapeutics (BTTX)

QualityStocks, MarketBeat and InvestorPlace reported earlier on Better Therapeutics (BTTX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Better Therapeutics Inc. (NASDAQ: BTTX) is a biotechnology firm that is focused on the development of prescription digital therapeutics.

The firm has its headquarters in San Francisco, California and was incorporated in 2015. Prior to its name change, the firm was known as Mountain Crest Acquisition Corp II. The firm serves consumers around the globe.

The company builds prescription digital therapeutics which deliver a new kind of behavioral therapy and create feedback mechanisms through the use of patient-generated and remotely-monitored data. It has designed a proprietary platform which is used to develop software-based, FDA-regulated solutions for various conditions. The company validates its software via multiple clinical trials and commercializes it to private health insurance firms.

The enterprise develops treatments that reverse illness progression, improve quality of life of patients and inform clinical decisions. They include BT-001 and BT-002, which have been developed to treat uncontrolled type 2 diabetes; BT-003 which is indicated for the treatment of hypertension; and BT-004, which is used to treat hyperlipidemia. It also develops a new form of behavioral therapy known as nutritional cognitive behavioral therapy, which is indicated for the treatment of patients with cardiometabolic ailments like type 2 diabetes, stroke and non-alcoholic fatty liver disease.

The company recently appointed a new chief strategy officer who has decades of experience in using technology to transform healthcare. This decision will help the company achieve its objective to transform the treatment of cardiometabolic diseases, which will in turn be good for its growth and investments into the company.

Better Therapeutics (BTTX), closed Thursday's trading session at $2.34, up 7.8341%, on 122,334,827 volume. The average volume for the last 3 months is 122.335M and the stock's 52-week low/high is $0.912/$29.40.

Shapeways Holdings (SHPW)

We reported earlier on Shapeways Holdings (SHPW), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Shapeways Holdings Inc. (NYSE: SHPW) is a digital manufacturing company that is engaged in designing, manufacturing and selling 3D printed products.

The firm has its headquarters in Long Island City, New York and was incorporated in 2008. Prior to its name change, the firm was known as Galileo Acquisition Corp. It operates as part of the printing and related support activities industry. The firm has nine companies in its corporate family and serves consumers around the globe, with a focus on Europe and the United States.

The company operates under a single segment, which offers 3D printing services to consumers. It is focused on providing digital manufacturing software solutions that increase access to industrial-grade additive manufacturing through the digitization of the end-to-end manufacturing process.

The enterprise uses about 10 additive manufacturing technologies to produce parts in roughly 90 finishes and materials. It offers services to 3D designers through its website, allowing them to upload and print their models. It uses its digital manufacturing platform to transform these digital designs into physical products.The enterprise’s software also supports consumers through the design, production, manufacturing and delivery process. In addition to this, its website provides a marketplace that allows designers to sell and share their products, which includes a range of personalized custom-made items like art products and jewelry.

The company is focused on growing its proprietary software platform and accelerating its investments to drive new sales growth by scaling its business development capabilities and using new 3D manufacturing technologies which will all have a positive influence on its growth.

Shapeways Holdings (SHPW), closed Thursday's trading session at $1.83, up 8.9286%, on 66,463 volume. The average volume for the last 3 months is 66,413 and the stock's 52-week low/high is $1.62/$12.81.

CYNGN Inc. (CYN)

The Street, StreetInsider, Money Morning, The Tycoon Report, The Trading Report, INO.com Market Report, InvestorPlace, MarketBeat, MarketClub Analysis, Money and Markets, AllPennyStocks, SmarTrend Newsletters, TradingAuthority Daily, Street Insider, The Stock Enthusiast and QualityStocks reported earlier on CYNGN Inc. (CYN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

CYNGN, Inc. (NASDAQ: CYN) is an AV (autonomous vehicle) technology firm which is engaged in the development of autonomous driving software for industrial and commercial machines.

The firm has its headquarters in Menlo Park, California and was incorporated in 2013. Prior to its name change, the firm was known as Cyanogen Inc. It operates as part of the computer systems design and related services industry, under the technology sector. The firm serves consumers in the United States.

The company’s platform uses machine learning, sensor fusion and computer vision to empower vehicles to adjust to complex environments, learn and share, which transforms them into self-driving and fully-integrated fleets of the future.

The enterprise is developing an internal tool suite and infrastructure dubbed CyngnEvolvem which facilitates machine learning and artificial intelligence training to improve models and algorithms. It also offers a simulation framework which ensures that the data gathered in the field can be applied to new releases. It also develops a customer facing tool suite for managing and monitoring autonomous vehicle fleets dubbed Cyngn Insight. This tool also aggregates and analyzes data. In addition to this, the enterprise develops a modular industrial vehicle autonomous driving software known as DriveMod.

The firm recently launched a turnkey autonomous vehicle solution known as the DriveMod Kit for the Stockchaser vehicles. This move creates opportunity for the adoption of the firm’s turnkey solutions for both new and retrofit vehicles, which will help extend its consumer reach and bring in additional revenues.

CYNGN Inc. (CYN), closed Thursday's trading session at $3.74, up 17.9811%, on 43,493,864 volume. The average volume for the last 3 months is 43.494M and the stock's 52-week low/high is $1.08/$9.91.

G1 Therapeutics (GTHX)

MarketBeat, StreetInsider, Kiplinger Today, StockMarketWatch, Schaeffer's, Barchart, Zacks, Trades Of The Day, The Street, The Online Investor, MarketClub Analysis and BUYINS.NET reported earlier on G1 Therapeutics (GTHX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

G1 Therapeutics, Inc. (NASDAQ: GTHX) (FRA: G1H) is a clinical-stage bio-pharmaceutical firm that is focused on discovering, developing and commercializing small molecule therapeutics for treating cancer patients.

The firm has its headquarters in Research Triangle Park, North Carolina and was incorporated in 2008, on May 19th by Normal E. Sharpless and Kwok-Kin Wong. It operates as part of the biotechnology industry, under the healthcare sector. The firm serves consumers in the United States.

The company is party to a license agreement with Arc Therapeutics to develop and commercialize a CDK2 inhibitor for veterinary and human uses; and Nanjing Sincere Dongyuan Pharmaceutical Co. Ltd, to develop and commercialize trilaciclin for any human indication. It is also party to a license agreement with Genor Biopharma Co. Inc and EQRx Inc. to develop and commercialize lerociclib for various indications.

The enterprise provides Cosela, which reduces chemotherapy-induced myelosuppression in patients with extensive stage small cell lung cancer. It is also developing an oral selective estrogen receptor degrader known as rintodestrant, for the treatment of HER2-negative and estrogen receptor-positive breast cancer; and an oral CDK4/6 inhibitor dubbed lerociclin for a range of oncology indications. The enterprise also develops a CDK4/6 inhibitor dubbed trilaciclin, which is undergoing a number of clinical trials evaluating its effectiveness in treating bladder cancer, triple negative breast cancer and colorectal cancer.

The firm recently released its latest financial results, which show an increase in its revenues. Its CEO noted that the firm was focused on serving patients with cancer and creating value for its shareholders, which will bolster its growth.

G1 Therapeutics (GTHX), closed Thursday's trading session at $5.24, off by 4.5537%, on 963,975 volume. The average volume for the last 3 months is 959,742 and the stock's 52-week low/high is $4.905/$24.12.

Cyclacel Pharmaceuticals (CYCC)

Greenbackers, The Street, MarketClub Analysis, Streetwise Reports, StreetInsider, BUYINS.NET, TraderPower, MarketBeat, StockEgg, Promotion Stock Secrets, QualityStocks, OTCPicks, PennyStocks24, Marketbeat.com, HotOTC, CRWEWallStreet, CoolPennyStocks, MicrocapVoice, Profit Confidential, StockMarketWatch, Street Insider, The Online Investor, The Bull Report, MegaPennyStocks, StockRich, PennyTrader Publisher, The Momentum Traders Network, MadPennyStocks, Penny Invest, PennyStockVille, PennyInvest, Wall Street Resources, BullRally, Stock Traders Chat, Energy and Capital, TopPennyStockMovers, SmarTrend Newsletters, ChartPoppers, Stockpalooza, InvestorsUnderground, The Penny Play, FNNO Newsletters, Wealth Daily, Investment Contrarians, NYC Marketing Inc, Stock Rich, Penny Detectives, Penny Stock Finder, PennyOmega, WealthMakers, Stock Source, Schaeffer's, SmallCapVoice, Stealth Stocks, Stock Beast, Stock Market Watch and Momentum Traders reported earlier on Cyclacel Pharmaceuticals (CYCC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) (FRA: UX14) is a clinical-stage bio-pharmaceutical firm that is focused on the development of drugs to help treat cancer and other proliferative illnesses.

The firm has its headquarters in Berkeley Heights, New Jersey and was incorporated in 1996, on August 13th by David Glover, David Philip Lane and Ronald J. Berenson. It operates as part of the biotechnology industry, under the healthcare sector. The firm serves consumers around the globe, with a focus on the United Kingdom and the United States.

The company is party to a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center, which entails clinically assessing the effectiveness and safety of some of its formulations in patients with myelodysplastic syndromes, acute myeloid leukemias, chronic lymphocytic leukemias and other advanced leukemias.

The enterprise’s development programs include a CDK inhibitor dubbed seliciclib, which is undergoing two clinical trials evaluating its effectiveness in treating rheumatoid arthritis and Cushing’s disease. It also develops a polo-like kinase inhibitor program dubbed CYC140, which is undergoing a phase II trial testing its efficacy in treating solid tumors and advanced leukemias. This is in addition to developing a cyclin-dependent kinase inhibitor termed fadraciclib, which has been developed to treat relapsed or refractory chronic lymphocytic leukemia and solid tumors.

The company’s current focus is on reaching its important milestones, which include conducting clinical trials of its formulations with cancer centers from different parts of the globe. The success and approval of its formulations will not only benefit patients with serious indications but also bring in more investments into the company.

Cyclacel Pharmaceuticals (CYCC), closed Thursday's trading session at $1.83, off by 7.1066%, on 46,166 volume. The average volume for the last 3 months is 46,166 and the stock's 52-week low/high is $1.79/$7.95.

Core Scientific (CORZ)

Trades Of The Day and MarketBeat reported earlier on Core Scientific (CORZ), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Core Scientific Inc. (NASDAQ: CORZ) (FRA: 7ZD0) is engaged in the provision of net carbon-neutral digital asset mining and blockchain infrastructure solutions.

The firm has its headquarters in Austin, Texas and was incorporated in 2017, on December 13th. Prior to its name change, the firm was known as Power & Digital Infrastructure Acquisition Corp. It operates as part of the software-infrastructure industry, under the technology sector. The firm has three companies in its corporate family and serves consumers in the United States.

The company operates through the following segments: Hosting and Equipment sales segments, which comprise of equipment sales to consumers, 3rd party hosting business and blockchain infrastructure. The blockchain business earns revenue by offering hosting services and selling consumption-based contracts. Its mining segment comprises of digital asset mining. The digital mining segment generates revenue from operating the firm’s computer equipment to process valid transactions on certain digital asset blockchain networks. The segment also receives digital currency assets. The company operates data centers in Texas, North Dakota, North Carolina, Kentucky and Georgia.

The enterprise provides blockchain hosting services with deployment and offers proprietary thermodynamic management, racks, power, 24/7 security and redundant connectivity. It also offers its MinderOS and Minder proprietary software platforms, which in turn offer custom firmware and infrastructure management.

The firm is currently focused on building value for its shareholders, which will not only encourage more investments into the firm but also bolster the firm’s overall growth.

Core Scientific (CORZ), closed Thursday's trading session at $5.32, off by 7.6389%, on 2,249,787 volume. The average volume for the last 3 months is 2.249M and the stock's 52-week low/high is $5.06/$14.98.

Ikena Oncology (IKNA)

MarketBeat and StocksEarning reported earlier on Ikena Oncology (IKNA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Ikena Oncology Inc. (NASDAQ: IKNA) is a targeted oncology firm that is engaged in the development of drugs designed for biomarker-defined patients’ groups for certain unmet needs.

The firm has its headquarters in Boston, Massachusetts and was incorporated in February 2016 by George Georgiou and Mark Manfredi. Prior to its name change the firm was known as Kyn Therapeutics. It operates as part of the pharmaceutical and medicine manufacturing industry, under the healthcare sector. The firm has two companies in its corporate family and serves consumers around the world, with a focus on the United States.

The company develops treatments which possess the potential in combination and as single agents to target underlying mechanisms which drive the survival of cancer as well as its growth and spread.

The enterprise’s programs include an oral selective EP4 receptor antagonist dubbed IK-007, which has been designed to treat microsatellite stable colorectal cancer; an oral inhibitor of aryl hydrocarbon receptor known as IK-175; a small molecule inhibitor program in the RAS signaling pathway that has been developed to target ERK5; and an oral small molecule inhibitor of the transcription factor in the Hippo signaling pathway and the transcriptional enhance associate domain, dubbed IK-930.

The company, which recently announced its latest financial results, remains focused on advancing its targeted oncology programs to help address the unmet needs of cancer patients. It is well positioned to execute its goals, which will positively influence its growth and help create value for its shareholders.

Ikena Oncology (IKNA), closed Thursday's trading session at $4.17, up 9.1623%, on 274,311 volume. The average volume for the last 3 months is 274,311 and the stock's 52-week low/high is $2.83/$26.4899.

Essa Pharma (EPIX)

TradersPro, MarketBeat, StockMarketWatch, TraderPower, The Dean, OTCPicks, StreetInsider, Stock Guru, MicrocapVoice and MarketArmor.com reported earlier on Essa Pharma (EPIX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Essa Pharma Inc. (NASDAQ: EPIX) is a clinical stage pharmaceutical firm that is engaged in the development of new and proprietary therapies for treating prostate cancer.

The firm has its headquarters in Vancouver, Canada and was incorporated in 2009, on January 6th by Raymond J. Andersen and Marianne D. Sadar. It operates as part of the biotechnology industry, under the health care sector. The firm has two companies in its corporate family and serves consumers around the globe.

The company is party to collaboration agreements with Astelllas Pharma Inc.; Janssen Research and Development LLC; Bayer Consumer Car AG; and Caris Life Sciences Inc.

The enterprise’s product pipeline comprises of an oral, small molecule candidate dubbed EPI-7386, which is undergoing a phase I clinical trial evaluating its effectiveness in treating patients with metastatic castration-resistant prostate cancer, which is also resistant to standard of care treatments. Prostate cancer is primarily driven by the androgen receptor. Current standards of care (anti-androgen therapies) usually target one end of the receptor, which causes resistance to treatments. The enterprise’s formulation has been designed to inhibit the N-terminal domain of the androgen receptor, which isn’t targeted by anti-androgen therapies and is on the opposite side of the ligand binding domain.

The company plans to enter into more clinical collaborations which will offer it numerous growth opportunities. This move will also bring in more investors into the company, which will be good for its investments and help bolster the firm’s growth significantly.

Essa Pharma (EPIX), closed Thursday's trading session at $5.71, off by 4.515%, on 198,085 volume. The average volume for the last 3 months is 198,085 and the stock's 52-week low/high is $5.46/$36.00.

Pasithea Therapeutics Corp.'s (KTTA)

QualityStocks, AwesomeStocks, MarketClub Analysis, Broad Street, StockWireNews, StockStreetWire, Small Cap Firm and Fierce Analyst reported earlier on Pasithea Therapeutics Corp.'s (KTTA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Pasithea Therapeutics’ (NASDAQ: KTTA) CEO, Dr. Tiago Reis Marques, a psychiatrist at one of the top psychiatry centers in the world, a fellow at Imperial College London and a lecturer at the Institute of Psychiatry, King’s College London, was featured in a recent Forbes article. The piece, titled “You May Soon Find Mental Health Help from Psychedelic Drug-Assisted Psychotherapy in the Metaverse,” discusses record levels of mental health issues driven by the pandemic, social unrest, partisan politics, cable news, social media and Russia’s war against Ukraine. To learn about ways to help with this mental health epidemic, the article’s author and Forbes’ senior contributor, Jack Kelly, spoke with Dr. Marques. He shared the promising innovation of psychedelic, drug-assisted psychotherapy—the medically approved use of MDMA, psilocybin and LSD as a component of elevated psychotherapy programs.

“With these new clinics, we will broaden our London footprint and start offering pharmacy services and new treatment options, bringing important and novel mental health therapies to an ever-growing number of people,” said Dr. Marques. “In addition to pharmacy services, our London clinics will offer other psychiatric treatment therapies, including repeated transcranial magnetic stimulation in addition to IV ketamine.”

To view the full article, visit https://ibn.fm/ojeWy

About Pasithea Therapeutics Corp.

Pasithea Therapeutics is at the forefront of research into mental health and brain disorders. The biotech company is aiming to solve one of the world’s biggest clinical problems: brain disorders. The long-term aim is to translate research into clinic-ready drugs. Pasithea’s primary focus is on drug development with the goal of its scientific team to develop new medications that provide better and longer-lasting results for individuals with mental health issues. For more information about the company, visit www.Pasithea.com.

Pasithea Therapeutics Corp.'s (KTTA), closed Thursday's trading session at $1.08, off by 7.6923%, on 206,695 volume. The average volume for the last 3 months is 206,695 and the stock's 52-week low/high is $0.93/$8.50.

Industrial Nanotech Inc. (INTK)

Stock Guru, UndiscoveredEquities, OTCPicks, The Cervelle Group, Industrial Nanotech, PennyTrader Publisher, Stock Stars, TheStockWizards.net, QualityStocks, Stocks That Move, MadPennyStocks, PennyInvest, Greenbackers, FeedBlitz, CoolPennyStocks, HotOTC, PennyStockVille, BullRally, SmallCapVoice, WiseAlerts, StockEgg, StockGuru, StockRich, The Cevelle Group and Pumps and Dumps reported earlier on Industrial Nanotech Inc. (INTK), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Industrial Nanotech (OTC: INTK), a global nanoscience solutions and product development leader, today announced its receipt of a request for a specification for a tank project from an existing customer, Pemex. According to the update, the total number of gallons is 3,600, with $622,800 as the retail price for that product volume before standard volume discounts. The requested documents were submitted yesterday. “Pemex has used our products successfully before, so we expect the relationship to be successful yet again,” said Stuart Burchill, CEO/CTO of Industrial Nanotech. “One of the prior Pemex projects used our High Heat product on large valves on one of their offshore drilling platforms and is featured in our Oil & Gas product literature.”

To view the full press release, visit https://ibn.fm/Ec7P0

About Industrial Nanotech Inc.

Industrial Nanotech is a global nanoscience solutions and product development leader. For more information about the company, visit www.Industrial-Nanotech.com.

Industrial Nanotech Inc. (INTK), closed Thursday's trading session at $0.02, off by 14.8936%, on 20,945,940 volume. The average volume for the last 3 months is 20.946M and the stock's 52-week low/high is $0.0001/$0.0523.

The QualityStocks Company Corner

Mullen Automotive Inc. (NASDAQ: MULN)

The QualityStocks Daily Newsletter would like to spotlight Mullen Automotive Inc. (MULN).

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, has announced that it will be adding its Mullen FIVE RS model to its summer roadshow tour. The company has been touring the country in what it calls a “strikingly different” test-drive opportunity. The event has featured the Mullen FIVE EV Crossover; adding the Mullen FIVE RS will allow those who visit the event to see the new electric vehicle up close although, because of its high-powered capabilities (it can go from 0 to 60 mph in 1.95 seconds), visitors will not be able to test drive the car. Rather, those at the event will be able to experience the Mullen FIVE RS as a rider, with a professional IndyCar race car driver taking the wheel. Mullen also announced that the unique roadshow will continue in 2023, with stops planned in Los Angeles, Las Vegas, Austin, Ft. Lauderdale, Charlotte, New York, Detroit, Indianapolis and Wendover at the Bonneville Salt Flats. “We're adding a spring segment in 2023 with additional stops and increasing the number of Mullen FIVEs on tour to ensure as many people as possible can experience the Mullen FIVE," said Mullen Automotive CEO and chair David Michery in the press release. “The RS is a personal project, and I fully intend for this EV to be one of the fastest and most exhilarating vehicles in the world. I'm excited to give people an up-close and personal glimpse of what we are working on. The second leg of the tour will include top racetracks around the country, including a stop at the Bonneville Salt Flats, which is an iconic location for vehicle testing and land speed records.” To view the full press release, visit https://ibn.fm/ahHQB. Many see electric cars as the vehicles of the future, especially as the world transitions from the use of fossil fuels. However, some are concerned about how electric cars get their juice, which is by charging. No one wants to be stuck in the middle of nowhere with no battery left. Running out of power with no charging station is said to be one of the biggest obstructions to the mass adoption of electric cars. So to help address these concerns, the Biden administration is planning to install chargers to make it easier for owners of electric vehicles to charge their vehicles anywhere and at any time. As charging points become more readily available, we are likely to see a lot more people buying EVs from all available manufacturers such as Mullen Automotive Inc. (NASDAQ: MULN).

Mullen Automotive Inc. (NASDAQ: MULN) is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership.

Commencement of Trading on Nasdaq

On November 5, 2021, Mullen announced its commencement of trading on the Nasdaq Capital Market.

“Today is a monumental day for Mullen Automotive. I am especially proud of our team, investors and all who have believed in Mullen and taken us to this point as a publicly traded company on the Nasdaq Capital Market,” David Michery, CEO and Chairman of Mullen Automotive, stated in the news release. “Trading on Nasdaq now opens us up to new investors, both institutional and retail shareholders, and broadens our awareness and company profile, while increasing awareness of Mullen and our technology platform and opening new opportunities in EV and beyond. The road ahead has never been brighter for Mullen, and I am proud to lead us into the future.”

The milestone came in the wake of the company’s stock-for-stock merger with Net Element Inc.

The Mullen FIVE

The Mullen FIVE EV Crossover, debuting at the Los Angeles International Auto Show (LAIAS) on November 17, 2021, embodies Mullen’s Southern California roots with an inspired design focused on two complementary Golden State themes – California landscape and California urban.

The FIVE is built on an EV Crossover skateboard platform that offers multiple powertrain configurations and trim levels in a svelte design that is Strikingly Different™ and exciting to experience in person.

Prior to the start of LAIAS, the Mullen FIVE was selected as a finalist by the LA Auto Show for Top EV SUV in the ZEVA “People’s Choice” Awards.

LAIAS provides Mullen an opportunity to display multiple variants of the FIVE model while also showcasing its powertrain, battery and charging technology. The company intends to bring the FIVE to market in 2024, and reservations are currently open here.

Mullen’s development portfolio also includes EV Fleet Vans, which it intends to bring to market in Q2 2022, and the pure electric, high performance Mullen DragonFLY.

Expansion of Manufacturing Capacity

On November 2, 2021, Mullen announced plans to expand its facility in Robinsonville, Mississippi.

Mullen’s Advanced Manufacturing and Engineering Facility (AMEC) currently occupies 124,000 square feet of manufacturing space. The total available land on the property is over 100 acres, and Mullen is moving ahead with plans to build out another 1.2 million square feet of manufacturing space to support class 1 and class 2 EV cargo vans and the Mullen FIVE EV Crossover.

On the expanded site, Mullen plans to build a body shop, a fully automated paint shop and a general assembly shop.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working toward a sustainable future accessible to all by creating a suite of clean-energy electric vehicles at varied price points. With entirely U.S.-based manufacturing and operations, he is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Mullen Automotive Inc. (MULN), closed Thursday's trading session at $1.31, up 1.5504%, on 94,582,406 volume. The average volume for the last 3 months is 91.513M and the stock's 52-week low/high is $0.52/$15.90.

Recent News

Advanced Container Technologies Inc. (OTC: ACTX)

The QualityStocks Daily Newsletter would like to spotlight Advanced Container Technologies Inc. (OTC: ACTX).

  • Up to $400 million has been made available to support food purchases with emphasis on purchasing from underserved farmers, ranchers
  • Agency strengthens efforts to provide emergency food assistance, expand economic opportunity
  • ACTX GrowPods could be valuable tool in effort to build resilient local, regional food-production capabilities

In an effort to provide transform the food system and build a better food system after the global pandemic exposed weaknesses in the system, the U.S. Department of Agriculture (“USDA”) established a Local Food Purchase Assistance Cooperative Agreement Program (“LFPA”) last year (https://cnw.fm/omE5D). Advanced Container Technologies (OTC: ACTX), a company focused on the business of developing, manufacturing and selling advanced cultivation equipment, proprietary packaging systems, and a variety of other products, is ideally suited to help meet the needs of the new USDA initiative to build a new and more equitable food system (https://cnw.fm/gZf00). 

Advanced Container Technologies Inc. (OTC: ACTX) is in the business of selling and distributing self-contained, automated, indoor “micro-farms” called Grow Pods, along with related equipment and supplies. Additionally, the company designs and sells patented proprietary medical-grade plastic containers, known as the Medtainer®, that store and grind pharmaceuticals, herbs, teas and other solids or liquids.

ACTX is the leading distributor of Grow Pods. With a controlled environment, food and herbs can be grown without pesticides, harmful chemicals or risk of pathogen contamination, and with low energy consumption. Restaurants, grocery stores, non-profits, MSOs and entrepreneurs can use Grow Pods to ensure a fresh supply of ultra-clean produce year-round.

The company entered the Grow Pod business in October 2020 with its acquisition of all shares of Advanced Container Technologies Inc., a California corporation. As of February 28, 2022, ACTX is exploring the acquisition of the assets and the assumption of some or all of the liabilities of GP Solutions Inc., the developer and manufacturer of Grow Pods, for which ACTX is currently the sole U.S. distributor.

Because Grow Pods can be located almost anywhere, produce can be grown closer to the point of consumption and harvested at its peak, providing nutritious fruits and vegetables where needed. Indoor micro-farms, utilizing a practice known as vertical farming, have attracted the attention of governments and universities, which are now promoting vertical farming as a way to combat food insecurity and inequities.

The United States Department of Agriculture (USDA) has stated that vertical farming “is no longer a futuristic concept.” The department is enthusiastic about vertical farming, particularly those utilizing repurposed shipping containers, such as Grow Pods. Arizona State University reports that vertical farming reduces water use by 90 percent compared to conventional farming but produces 10 times the crop yield.

Products

Grow Pods

One of the company’s main business units is focused on selling advanced, self-contained hydroponic containers called Grow Pods. These unique and innovative automated systems are essentially micro-farms that can be placed virtually anywhere and, with their controlled and specially filtered environment, allow cultivation of a wide variety of crops, 365 days a year. The Grow Pod controlled environment offers major advantages for the production of high-value crops. The ability to grow year-round and the ability to cultivate in a smaller footprint using less water and power are some of the primary advantages of the system. Grow Pods offer constant temperature, humidity and airflow control, as well as automated watering and lighting schedules for optimal growth and minimal labor requirements, regardless of crop.

Containers

ACTX meets the needs of the pharmaceutical and medical markets, including the cannabis and hemp industries, with patented packaging systems. The company designs, customizes, brands and sells proprietary medical grade plastic containers that can store pharmaceuticals, herbs, teas and other solids or liquids, with a special built-in feature that can grind solids and shred herbs. The company’s flagship container product is the patented Medtainer®, a child resistant, medical-grade herb container and grinder that is water-tight, air-tight and smell proof. Packaging in the cannabis industry is critical, with numerous stringent regulations about how cannabis products must be packaged and labeled. ACTX also offers custom-branded, compliant vacuum seal bags and other retail container solutions.

Equipment and Supplies

ACTX markets and sells two principal products: Grow Pods, which are specially modified insulated shipping containers manufactured by GP Solutions Inc., in which plants, herbs and spices may be grown hydroponically in a controlled environment, and Medtainers®, which may be used to store pharmaceuticals, herbs, teas and other solids or liquids and can grind solids and shred herbs. The company also markets and sells various products related to Grow Pods and the Medtainer®, as well as providing private labeling and branding services for purchasers of Medtainers® and certain related products.

GP Solutions manufactures and sells other products, such as humidity controllers and LED lighting systems for vertical farming. The company’s specially designed lighting panels are programmed to emit the exact wavelength of light that each crop requires. The system has a daybreak-to-nightfall feature that gives plants the proper chromatic signals to grow rapidly and fruitfully. High efficiency LED light strips supply the crops with a red and blue light spectrum required for photosynthesis in the spectrum that plants need most.

Market Overview

The global vertical farming market is expected to reach $33.02 billion by 2030, according to a new report by Grand View Research. The market is forecast to expand at a CAGR of 25.5 percent from 2022 to 2030, according to Grand View. Escalating production of biopharmaceutical products, including cannabis, is anticipated to drive the market. The building-based segment of the market is expected to register a significant CAGR of 27.8 percent over the projected period. In addition, the climate control segment is expected to see high growth.

The global cannabis packaging market is expected to reach $14.34 billion by 2028, according to analysis by Reports and Data. The analysis forecasts 1,700 percent growth in cannabis users by the end of 2026, with packaging likely observing a whopping 26.42 percent growth in the forecast period. There are significant barriers to entry in the cannabis packaging market, giving an advantage to companies already established in the sector. These barriers include developing a thorough knowledge of the myriad regulations that govern cannabis packaging (which differ in each state), and child-resistance requirements.

Management Team

Douglas P. Heldoorn is the Founder and Chairman of Advanced Container Technologies Inc. He also holds the positions of President, CEO and COO at the company. Mr. Heldoorn has served on the Board of Directors since its inception in 2013. He has also previously held the position of Executive General Manager at Nissan Motor Corp.

Jeffory A. Carlson is CFO and Treasurer of ACTX. Mr. Carlson has also served as the company’s Corporate Controller since 2014.

Advanced Container Technologies Inc. (OTC: ACTX), closed Thursday's trading session at $0.985, up 9.4444%, on 774 volume. The average volume for the last 3 months is 774 and the stock's 52-week low/high is $0.66/$4.55.

Recent News

Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF)

The QualityStocks Daily Newsletter would like to spotlight Red White & Bloom Brands Inc. (OTCQX: RWBYF).

As more states legalize cannabis for medical and/or recreational purposes, a bigger proportion of the population can now readily access marijuana products from licensed outlets. According to research out of UC San Diego, a significant fraction of all new marijuana users are seniors. We offer the following tips to seniors who want to use medical or recreational marijuana for the first time. The legalization of cannabis in different states has given entrepreneurs an opportunity to come up with different cannabis products and ways to use those products. For example, there are cannabis edibles, suppositories, vape products, and smokable products, among many other administration methods. Do your research and select a consumption method that will suit your personal needs and preferences. Who knows, you might discover that the cannabis products from regulated companions like Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) give you a new lease of life!

Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) is a torchbearer blazing a new frontier in American cannabis by adhering to the highest ethical, manufacturing, educational, branding and employment standards available in the industry.

Red White & Bloom is a super state operator, leveraging a sizable footprint to dominate the areas in which it operates. CEO Brad Rogers and other management members have seen the struggles of multi-state operators who have spread themselves too thin, which is why Red White & Bloom is intent on dominating each state it enters before expanding further.

Although targeting individual states in the United States, the company is headquartered in Toronto, Canada. Red White & Bloom was established after privately held MichiCann Medical Inc. merged with publicly traded Tidal Royalty in 2019.

Brands

Red White & Bloom has entered strategic brand acquisitions and partnerships aimed at helping the company expand its presence and position as one of the largest players in the United States cannabis market. Red White & Bloom is always diligently searching for brands to acquire that will provide additional value to the company and expand its national footprint.

The company’s current brand portfolio includes:

  • Platinum Premium Cannabis Products (PV): Platinum uses innovative thinking, honesty and responsibility to remain at the forefront of the cannabis industry. PV holds itself and its partners to the highest standards, providing clean and safe CBD and THC products. In the company’s press release dated January 13, 2021, it reported system-wide sales of Platinum-branded products exceeding $2.8 million for the first week of January alone.
  • High Times®: In June 2020, the company acquired the licensing rights and branding of High Times dispensaries and High Times cannabis-based CBD and THC products in Michigan, Illinois and Florida. The company also acquired branding of High Times hemp derived CBD products nationally in the United States carrying the Culture® brand.
  • Mid-American Growers: Mid-American began as a family operation in 1971 in Granville, Illinois. The original 8-acre greenhouse has expanded to a 3.6-million-square-foot, state-of-the-art technology and science facility under glass. Mid-American’s product offerings include its CBD Icy Relief Salve, CBD Icy Relief Roll-on and CBD Gummies.

Retail Focus

Red White & Bloom is working to establish a significant retail presence across multiple jurisdictions. In Michigan, the company is invested in and has the rights to acquire (subject to regulatory approvals) a licensed operator that controls the assets of 18 dispensary locations throughout the state. Red White & Bloom is also pursuing opportunities in Florida aimed at making its proposed retail footprint compelling and attractive to the majority of cannabis consumers within each state.

Cultivation

Red White & Bloom is focused on standardization and quality, with everything guided by a relentless commitment to the highest standards. The company acquired a 3.6-million-square-foot standardized facility dedicated to helping it achieve premium value for the products it intends to cultivate.

As it continues to expand, the company remains committed to the practices that have guided its success in the past, including:

  • A top-down approach to cultivation developed under the guidance of PhDs with expertise in growing principles, SOPs and, most importantly, the science behind it all.
  • Commitment to exceeding the requirement of the states in which it operates. The company cut its teeth under the world’s first national cannabis purity regime – a regime that most new markets use as a benchmark – so quality is in its DNA.
  • Science-driven production methods supported by automated, perpetual, standardized operations that enable craft cannabis-like quality at an industrial scale.

Footprint

Assuming completion of the currently proposed investments and acquisitions, Red White & Bloom will be among the cannabis market’s largest companies, joining the ranks of a select few multi-state operators dominating the industry. Red White & Bloom currently has assets (closed and in closing stages) in Michigan, Illinois, Florida, California, Oklahoma and Massachusetts.

The company’s strategic acquisition and super state operator model, combined with its commitment to top-quality product and service, position it to become a leading player in the North American cannabis market.

When evaluated beside competitors in the cannabis space, Red White & Bloom boasts an extremely attractive valuation. While large cap cannabis firms serving North American markets averaged enterprise-value-to-EBITDA multiples of 14.9x as of December 2020, Red White & Bloom’s enterprise multiple was just 3.4x, as noted in the company’s latest investor deck.

In 2020, the cannabis market worldwide was valued at $24.6 billion. This amount is expected to expand at a CAGR of 14.3% from 2021 to 2028, resulting in a market size of $84 billion in 2028 (https://nnw.fm/f09ZL). Of the 2020 valuation, the largest revenue share (91.1%) was attributed to North American consumers (https://nnw.fm/vObW6).

Management Team

Brad Rogers is the CEO and Executive Chair of Red White & Bloom. He is a visionary for the future of cannabis and CBD products in the United States market, with a proven track record of building successful and profitable businesses in the rapidly expanding and new economic sector. Mr. Rogers was a part of the team that built one of the first commercially scaled production facilities in the world for medicinal cannabis. He also served as President for one of the leading licensed producers in Canada. Both of his ventures were successful, with a combined market cap of $2 billion.

Michael Marchese is the company’s Co-Founder and Marketing Advisor. He has played a crucial role in its development and organization, overseeing capital raises, acquisition strategy and brand identity. Mr. Marchese has a strong reputation and presence in the cannabis industry. He also co-founded and directed the branding of Aleafia Health Inc., which he continues to counsel. Through his branded company, Marchese Design, he has served as a highly trusted counselor to top-level execs, including C-Suite level employees, offering insights into the process of creating, building and maintaining brand identities.

Theo van der Linde is the CFO and Director of Red White & Bloom. He is a Chartered Accountant with 20 years of experience in finance, administration and public accounting. The experience he has acquired spans multiple industries, including mining, oil & gas, financial services, retail and manufacturing. For the last nine years, he has primarily focused his career on the mining industry, working with junior exploration and producing mining companies at various stages of growth in several jurisdictions. Mr. van der Linde is also the current President of Executive Management Solutions Ltd.

Red White & Bloom Brands Inc. (RWBYF), closed Thursday's trading session at $0.175, up 4.5088%, on 355,590 volume. The average volume for the last 3 months is 355,590 and the stock's 52-week low/high is $0.159/$1.21.

Recent News

SPYR Inc. (OTCQB: SPYR)

The QualityStocks Daily Newsletter would like to spotlight SPYR Inc. (OTCQB: SPYR).

SPYR (OTCQB: SPYR) is a technology company whose subsidiary, Applied Magix Inc., develops and resells Apple(R) ecosystem compatible products in the growing multibillion-dollar smart home and connected car markets. The company today announced that it is considering developing software for non-branded smart products in order to improve the user experience (“UX”), enhancing available products without the burden of new hardware development. “In our research into viable products to manufacture or carry, we have come across a number of manufacturers in China, with well-engineered, often excellent hardware, yet abysmally poor software. Since the software is the main point of interaction for customers, badly designed software inevitably results in a bad customer impression of the product,” said Applied Magix CEO Dr. Harald Zink. “By selecting well-engineered products, and re-engineering a better software product to accompany it, we hope to gain the best of both worlds — low development costs (as we don’t have to develop new hardware) and additions to our product line in the form of both the software product, as well as reselling the hardware product with minimal overhead.” To view the full press release, visit https://ibn.fm/jEfmh

SPYR Inc. (OTCQB: SPYR), dba SPYR Technologies, is a technology company which, through its Applied MagiX Inc. subsidiary, develops and resells Apple®-ecosystem-compatible products with an emphasis on the growing, multibillion-dollar Internet of Things (IoT) Smart Home and Connected Car markets.

SPYR continues to identify and target acquisitions with an aim of growing its footprint in the industry and expanding the products it offers consumers, including companies developing artificial intelligence and smart-technology products. In 2020, SPYR acquired Applied MagiX Inc., a registered Apple developer and reseller of Apple ecosystem compatible products with an emphasis on the smart home market, as a wholly owned subsidiary. Applied MagiX operates in the IoT market and, more specifically, the segment of the market related to the development, manufacture and sale of devices and accessories specifically built on Apple’s HomeKit® framework. These products work within the Apple HomeKit ecosystem and are exclusive to the Apple market and its consumers.

Initially, while working to develop, manufacture and sell its own line of branded products, Applied MagiX will be sourcing HomeKit products and accessories from worldwide manufacturers, vetting and selecting best-of-breed products, selling them directly to consumers and supporting them. The company focuses on Apple consumers – a target market with higher disposable income and a demonstrated willingness to pay a premium for quality products. On average, Apple product users spend roughly twice as much on technology as other smartphone users. Those who purchase smart home products spend more than $3,000 on average.

By creating smart hardware and software solutions exclusively for Apple consumers, SPYR addresses a problem faced by that market – having few “smart” devices that integrate with Apple’s HomeKit, despite being the most affluent and loyal consumers of tech products.

Products

The company’s Applied MagiX subsidiary offers multiple product lines to its target markets. First, the subsidiary is a reseller of third-party manufactured Apple HomeKit and Apple CarPlay compatible products. HomeKit comes pre-installed on every new iPhone, while the CarPlay platform is licensed by all major auto manufacturers. Applied MagiX identifies white label products, applies the company’s branding, improves the software and sells these improved products to consumers. Finally, Applied MagiX is developing its own proprietary line of smart home and connected car products, including Apple-compatible home cameras, sensors and alarms, as well as additional Apple-compatible smart car products in the iOS ecosystem.

Among the subsidiary’s products sold to consumers are:

  • The MagixDrive Wireless CarPlay adapter, which allows users to access CarPlay wirelessly using their iPhones
  • The HomeKit Secure Video Camera with iCloud Storage
  • The Multipurpose Sensor with Alarm
  • The Environment and Motion Sensor
  • The Window and Door Contact Sensor

Market Outlook

According to Statista, the global smart home market is expected to generate revenue of more than $104 billion in 2021. The market is forecast to hit more than $187 billion in revenue by 2025, recording a CAGR of 15.75 percent.

The number of active households in the worldwide smart home market is expected to reach nearly 500 million by 2025. Household penetration is just over 12 percent in 2021 and is projected to nearly double by 2025 to more than 22 percent.

Allied Market Research valued the global connected car market at more than $63 billion in 2019 and projected a CAGR of 17.1 percent, which would push revenue to more than $225 billion by 2027. Allied identified rising consumer demand for connectivity solutions, surging need for constant connectivity, increasing dependency on technology and an upsurge in tech-savvy population as key factors driving the projected growth of the connected car market.

Management Team

James R. Thompson is the CEO, President and General Counsel of SPYR. Over the past 28 years, Mr. Thompson has deftly managed a colorful spectrum of legal clients and situations. In the process, he has helped many companies – both large and small – thrive. Now he welcomes the challenge to take the company and his career in an entirely new direction. A native of Philadelphia, he holds a J.D. from Rutgers University and a Bachelor of Science from the University of Denver.

Jennifer Duettra is the Executive Vice President of SPYR. She brings a great deal of knowledge in mobile gaming and pop culture to the company. She is an attorney and was thrilled by the prospect to combine her law experience with a chance to be creative. She is a native of Colorado and received her Bachelor of Arts in Political Science and Speech Communication from Colorado State University. She holds a J.D. from Harvard University.

Trang Nguyen is the CFO of SPYR. From 2019 to 2020, she served as the Financial Reporting Manager for Del Taco, where she was responsible for the preparation and filing of periodic financial reports with the U.S. Securities and Exchange Commission. From 2016 through 2019, Ms. Nguyen was Accounting Manager for Pinnacle Tax Accounting in Los Angeles, California. She was a part of Ernst & Young’s audit team in Los Angeles from 2006 to 2008, leading engagements on interim and year-end ad SOX 404 auditing procedures for major enterprise accounts. Ms. Nguyen holds a Bachelor of Art, Business Economics (Minor in Accounting) from the University of California, Los Angeles. She is a certified public accountant with an inactive license.

Dr. Harald Zink is the CEO, Founder and Chief Product Architect of SPYR subsidiary Applied MagiX. Prior to founding Applied MagiX, he was Director of Technologies and later Vice President of Technologies at Sarkissian Productions in Los Angeles. He also served as Director of Technologies at SMZ Technologies and, for more than 17 years, as Macintosh Technology Consultant to The Walt Disney Studios in Burbank, California. He speaks five languages and holds degrees from the University of California, Riverside.

Kelly Clark is the COO of Applied MagiX. Before joining the subsidiary, he worked as Vice President of Sales Operations at TruClear Global. Prior to that, Mr. Clark was Senior Director of Program Management at Pacific Group Ventures and Operations Manager at Barco. He has also held operations management positions at Deluxe Digital Studios and Sony Pictures Entertainment. Mr. Clark holds a bachelor’s degree in international business from the University of Southern California.

SPYR Inc. (OTCQB: SPYR), closed Thursday's trading session at $0.0396, up 1.7995%, on 298,801 volume. The average volume for the last 3 months is 298,801 and the stock's 52-week low/high is $0.02355/$0.12.

Recent News

Correlate Infrastructure Partners Inc. (OTCQB: CIPI)

The QualityStocks Daily Newsletter would like to spotlight Correlate Infrastructure Partners Inc. (OTCQB: CIPI).

  • Correlate focuses on enabling building owners to reduce their facilities’ energy use or install clean energy solutions such as solar energy
  • The company designs, engineers, finances, and builds such solutions and other upgrades, enabling owners, who may include real estate investment trusts (“REITs”), to meet their Environmental, Social, and Governance (“ESG”) targets
  • Investors are increasingly conscious about whether companies espouse ESG values, and Correlate is helping REITs fulfill such requirements
  • Recently, Correlate announced it has entered a contract for a major rooftop solar energy project in New Jersey

Correlate Infrastructure Partners (OTCQB: CIPI) is a portfolio-scale real estate platform focused on eliminating barriers for large-scale property owners looking to optimize their buildings’ energy footprint and meet their sustainability goals. The company recognizes that while owners understand that they can reduce energy use by installing better technologies or meet their sustainability objectives by generating clean energy onsite, they face a decision-making dilemma. Usually, property owners find it difficult to establish the right approach. Correlate Infrastructure Partners (OTCQB: CIPI) today announced that final engineering, permitting and interconnection work has begun on the Geneva, Illinois, facility where the company has contracted to install a large-scale rooftop solar project. The massive project is being constructed at the headquarters of Continental Envelope and is located at the company’s manufacturing plant, which has the capacity to produce 2 billion envelopes per year. The clean energy system complements Continental’s “Pushing the Envelope” Community Gardens surrounding the property. “Correlate Infrastructure Partners loves supporting ESG-focused businesses that are making a true difference in their industries and communities. This attractive project makes clear that sustainability and profitability are no longer at odds,” said Todd Michaels, CEO of Correlate. “This is a call to action, Chicagoland! We are grateful to partner with this innovative family business that shows the printing industry can be more efficient and renewable without compromising reliability or profitability.” To view the full press release, visit https://ibn.fm/4tYrg

Correlate Infrastructure Partners Inc. (OTCQB: CIPI), formerly Triccar Inc., through its two subsidiaries, Correlate and Solar Site Design, offers a complete suite of proprietary clean energy assessment and fulfilment solutions for the commercial real estate industry. The company believes scaling distributed clean energy solutions is critical in mitigating the effects of climate change. CIPI is at the forefront in creating an industry-leading energy solution and financing platform for the commercial and industrial sector. The company sees tremendous market opportunity in reducing site-specific energy consumption and deploying clean energy generation and energy efficiency solutions at scale.

The opportunity exists to remove friction between today’s legacy finance process and the needed clean-energy upgrades developed within the company’s program technologies. For the U.S. to reach its 2050 carbon goals, 200,000 commercial buildings must be retrofitted every year until that date. That represents approximately a 5-10x increase over the 2022 industry process run rate.

CIPI announced completion of its acquisition of 100% of the equity of Correlate Inc. and Loyal Enterprises LLC dba Solar Site Design on December 28, 2021. The company notes these acquisitions occurred at a key inflection point of its growth. CIPI currently enjoys channel and sales partnerships with Fortune 250 companies and a strong, proven industry network.

The company’s transparent, leading-edge model changes value delivery for both facility owners and proven solution providers seeking scale. CIPI believes its rapid growth is due to industry demand for actionable, cashflow positive energy programs and the underlying carbon reduction mandates taking effect globally.

CIPI has filed with the SEC for a name change to Correlate Infrastructure Partners Inc., which will more closely reflect its new platform and growth focus. The company has been aggressively moving to rebrand, with efforts including a revised website, investor presentation materials and an investor relations awareness campaign. The company’s shares will continue to trade on the OTCQB Venture Market under the current ‘CIPI’ ticker symbol until changes are approved.

Subsidiaries

Correlate, founded in 2015, is a portfolio-scale development and finance platform offering commercial and industrial facilities access to clean electrification solutions focused on locally-sited solar, energy storage, EV infrastructure, and intelligent efficiency measures. Its unique data-driven approach is powered by proprietary analytics, concierge subscription services, and a highly scalable national fulfillment network to help building owners profit from fully funded, turnkey decarbonization and facility health programs. The platform is designed for commercial and industrial real estate owners seeking to significantly improve net operating income while meeting carbon reduction goals. The platform provides energy programs for commercial property portfolios and requires no upfront capital. Client organizations reduce their risk and generate more profits by leveraging Correlate’s unique payment programs to put more cash in the bank. Deploying Correlate’s strategic energy programs and energy management systems allows property-owning organizations to complete big energy changes across their portfolios.

Solar Site Design, founded in 2013, is a U.S. Department of Energy Sunshot Catalyst winner that provides customer acquisition and project development tools for the commercial solar industry. Its commercial marketplace platform connects highly qualified project opportunities to leading solar construction companies nationwide. The Solar Site Design platform gives commercial and industrial property owners access to the best price for a commercial solar system. Commercial solar analysts provide property owners a site assessment and working project proposal. Solar Site Design’s team of solar engineers finalize the design while approved financing providers help clients explore financing options for their projects. Then, approved contractors in Solar Site Design’s Marketplace bid on the projects, ensuring commercial and industrial property owners get the best estimates for their projects. Solar Site Design’s marketplace process promotes transparency and fair pricing. Its team of experts has nearly 20 years of experience in the solar industry. Only reputable, experienced, certified (NABCEP), licensed, bonded and insured contractors are accepted into the Solar Site Design Marketplace.

Market Outlook

CIPI is in a rapidly growing market with a unique offering to address a total market of more than 5.9 million commercial buildings in the United States, according to the U.S. Energy Information Administration. Currently, the company’s wholly owned subsidiaries, Correlate and the Solar Site Design, have an opportunity pipeline of over $100 million in commercial projects with more than $20 million in awarded backlog. According to the Rocky Mountain Institute, portfolio energy optimization is a $290 billion market in the United States driving deep financial savings and energy efficiency across the commercial sector.

Commercial buildings consume more than 35% of the generated electricity in the U.S. and are underperforming in energy efficiency at every level. These buildings waste energy, emit too much carbon, and are too costly for owners and occupants, but retrofits are not happening at the rate or scale needed.

In today’s real estate market, portfolio property owners own most commercial buildings. Yet most building efficiency work is focused on single buildings, thereby missing the distinct needs of this owner class which has very different needs than traditional owner-occupiers. The diverse nature of commercial buildings, combined with technology and performance uncertainty, make simple energy optimization initiatives – which could greatly reduce energy use and improve building value – financially unattractive, resulting in slow adoption rates. CIPI’s financial instruments and software breakdown this issue known as the “split incentive”, unlocking the majority of the addressable market.

Management Team

CIPI has in place a nationally recognized management team that has been active in the energy market since 2005.

Todd Michaels is President and CEO of CIPI and founder of Correlate. He formerly served as Vice President for Innovation at SunEdison and Senior Director Distributed Solar at NRG Energy. He founded Correlate in 2015 and has 16 years of experience in the energy industry. He graduated from Indiana University with a B.S. in Computer Information Systems.

Channing Chen is CFO at CIPI and Correlate Inc. and brings over 16 years of experience in the solar industry as a developer, financier, and business unit leader. He has held executive management roles at Solar Power Partners (acquired by NRG Energy), where he was a founding employee, SunEdison, and NRG Energy (NYSE: NRG). Most recently, Mr. Chen was founder and Managing Partner at Breakaway Energy Partners LLC – a distributed energy financing and market-making platform. To date, Mr. Chen and his teams have raised over $1.5 billion in financing across residential, commercial, and utility scale solar and energy storage projects representing over 400 MWs. He holds a B.A. in Environmental Chemistry from the University of California at San Diego and an MBA from the University of Southern California. He is also an advisor and early-stage investor to several startup companies in the renewable energy space.

David Bailey is Chief Revenue Officer of Correlate Inc. With over 15 years of executive sales, supply chain management, and energy efficiency experience, he is responsible for ensuring the success of the National Commercial Sales Unit across multiple regional project teams. Mr. Bailey created and launched the Transformation Services team while at Wesco for its multibillion-dollar Distributed Energy Resource division, formerly Westinghouse. His focus was on IoT-enabled efficiency and plant floor automation-based services. Before that, he spent several years in Global Account Sales Management, with GE Supply as a Program Manager, and is a Commercial Leadership Program graduate. Mr. Bailey received his B.S. in Mechanical Engineering from the University of Kentucky.

Jason Loyet is VP of Commercial Sales of Correlate Inc. He is a cleantech executive with over 20 years of experience leading high growth solar energy and software start-ups. Mr. Loyet is a U.S. Department of Energy SunShot Catalyst award winner for his work building the Solar Site Design technology platform. Before joining the solar energy industry in 2005, he founded and sold two software companies in the streaming media (GlobalStreams) and newspaper publishing (MyCapture) industries. Mr. Loyet currently serves as a Member of the Board of Directors for the Tennessee Solar Energy Industry Association (TenneSEIA).

Deke Welling is Head of Project Development and Fulfillment Services at Correlate Inc. He has over 19 years’ experience in the energy industry with an emphasis on renewables and energy efficiency over the past seven years. Prior to entering the renewables sector, Mr. Welling was the CEO of Welling Resources, an energy development company focused on the exploration of oil and natural gas reserves in the U.S. It was this experience that led him into the renewables sector and leading a charge for more sustainable resources. Additionally, Mr. Welling also served as the CEO of Circle L Solar Inc., a top 100 solar installer in the United States since 2016. Through his leadership, Circle L Solar experienced a growth rate of over 2,250% from 2016 to 2019, resulting in his company being listed on the Inc. 5000 list of the fastest growing private companies in the U.S. (Rank #176) and being named ‘Top Energy Company’ and ‘Entrepreneur of Year for the Energy Industry’ by the American Business Awards® in 2019 and again for ‘Entrepreneur of the Year’ in 2021.

Kevin Warren is Head of Construction and Development Engineering at Correlate Inc. He is a solar veteran with over 12 years of experience in the field. Prior to co-founding CLS, Mr. Warren was the owner of Beacon Consulting and has originated, consulted, designed and/or engineered over 122 MW of PV installations ranging from small commercial to utility scale projects throughout Texas, California, Colorado and North Carolina. He holds a Photovoltaic Technical Sales Professional Certification from the North American Board of Certified Energy Practitioners and certifications from Solar Energy International in PV Installation, PV Technical Sales, PV battery-based design, PV design and engineering, and PV operations and maintenance. Along with PV expertise, Mr. Warren is a LEED Green Building Associate, a certified building analyst from the Building Performance Institute, a Certified Renewable Energy Professional from the Association of Energy Engineers and holds a designation in High-Performance Sustainable Buildings from the BOMI Institute. He studied Electrical Engineering at the University of Texas at Arlington.

Tom Kunhardt is Director of Customer Success at Correlate. He previously held a similar position at Clean.Tech and was Corporate Trainer, Learning & Development, at NRG Energy. He has 15 years of experience in the solar and clean energy industries helping homeowners and businesses find solutions to their energy needs. He holds a bachelor’s degree from the University of Massachusetts.

Correlate Infrastructure Partners Inc. (OTCQB: CIPI), closed Thursday's trading session at $1.35, even for the day, on  volume. The average volume for the last 3 months is 2,400 and the stock's 52-week low/high is $0.30/$3.25.

Recent News

Knightscope, Inc. (NASDAQ: KSCP)

The QualityStocks Daily Newsletter would like to spotlight Knightscope, Inc. (NASDAQ: KSCP).

Knightscope (NASDAQ: KSCP), a developer of advanced physical security technologies focused on enhancing U.S. security operations, today announced that it has executed a new contract with a New York shopping center owner. The announcement reads, “Seven years ago yesterday, on Star Wars Day, Knightscope deployed its first robot at a popular Silicon Valley mall — an expanding use case with proven, ongoing successes. Protecting large parking lots and structures by enhancing existing security operations with a K5 Autonomous Security Robot (‘ASR’) helps to deter common challenges among mall owners and management companies such as trespassers, criminal mischief, and catalytic converter theft, while ensuring the safety of employee and patron vehicles to help promote a more enjoyable and lucrative shopping experience.” To view the full press release, visit https://ibn.fm/yZM4A

Knightscope, Inc. (NASDAQ: KSCP), founded in 2013 and based in Mountain View, California, is a leader in the development of autonomous security capabilities targeting to disrupt the $500 billion security industry. Knightscope’s technology uniquely combines self-driving technology, robotics, artificial intelligence and electric vehicles.

Knightscope designs and builds Autonomous Security Robots (ASRs) that provide 24/7/365 security to the places you live, work, visit and study. The company’s client list covers public institutions and commercial business operations, including multiple Fortune 1000 companies to date. These ASRs have been proven to enhance safety at hospitals, logistics facilities, manufacturing plants, schools and corporations. ASRs act as highly cost-effective complementary systems to traditional security and law enforcement officials, providing an additional advantage by continuing to offer uninterrupted patrolling capabilities across the country.

The company’s ASRs have assisted in the arrest of suspects involved in crimes ranging from armed robbery to hit-and-runs. Their machine-embedded thermal scanning capability even aided in preventing the breakout of a major fire. You can learn more about the crime fighting wins at www.knightscope.com/crime

The company has achieved several milestones since its creation in 2013, including:

  • Establishing itself in a 15,000-square-foot facility located in Mountain View, California, in the heart of Silicon Valley, where Knightscope designs, engineers and builds its technology (Made in the USA)
  • Operating for more than 1 million hours in the field and securing contracts across five time zones, from Hawaii to Rhode Island
  • Raising over $100 million since inception to build its technology from scratch and generating over $13 million in lifetime revenue, validating both the market opportunity and the technology

Growth Capital & Proposed Nasdaq Listing

With backing from more than 28,000 investors and four major corporations and over $100 million raised since inception, Knightscope is poised to be an industry leader in the future of public safety and security.

On December 1, 2021, Knightscope announced the commencement of an offering of up to $40 million of its Class A common stock, with shares to be listed immediately following closing on the Nasdaq Global Market under the ticker symbol ‘KSCP’. The offering is for up to 4 million shares priced at $10 per share. Learn more at www.knightscope.com/investors

Company Mission – Reimagining Public Safety

Knightscope’s long-term vision has an eye on the greater good. The company’s mission is to make the United States of America the safest nation in the world while supporting the 2+ million law enforcement and security professionals across the country.

Crime has an estimated negative economic impact in excess of $2 trillion annually. As crime is reduced, positive impacts will likely be realized across several aspects of society, including housing, financial markets, insurance, municipal budgets, local business and safety in general.

Knightscope CEO William Santana Li was interviewed by Kevin O’Leary, more commonly known as Shark Tank’s Mr. Wonderful. When asked to explain how the benefits provided by the ASRs outrank a human doing the same job, Li said, “First, just the simple presence of a physical deterrent causes criminal behavior to change. Second, the machines are self-driving cars that patrol all around and recharge themselves. They also generate 90 terabytes of data per year. No human would ever be able to process that. The robots are intended to be eyes and ears for the humans, not a one-to-one replacement.”

The Knightscope solution to reduce crime combines the physical presence of ASRs, sometimes referred to as proprietary Autonomous Data Machines, with real-time onsite data collection and analysis. The ASRs are fitted with eye-level 360° cameras, thermal scanning, public address announcements and various other features that work in tandem with humans to provide law enforcement officers and security guards unprecedented situational awareness.

Those 90 terabytes of data are then formatted in a useable way, so law enforcement can leverage that information and execute their responsibilities more effectively.

Public Safety Innovation

The company’s recurring revenue business model is set up to mimic the recurring societal problem of crime, and it takes into consideration the fact that innovation in the security and public safety industry has been stagnant for decades. Because the traditional practices of the sector have remained unchanged for years, automation has potential to drive substantial cost savings – and significant improvement in capabilities.

Human security guards are one of both the largest expenses and the largest liabilities for companies. Knightscope’s robots are offered at an effective price of $3 to $9 per hour, compared with approximately $85 for an armed off-duty law enforcement officer and $15 to $35 for an unarmed security guard.

This innovation has the potential to drive considerable cost savings. Based on these estimates, manufacturing costs can be recovered as soon as the first year of operation.

Product Offerings

The company has nine patents and a framework of unique intellectual property. Knightscope currently offers a K1 stationary machine, a K3 indoor machine and a K5 outdoor machine. A K7 multi-terrain four-wheel version is in development.

The ASRs autonomously patrol client sites without the need for remote control, providing a visible, force multiplying, physical security presence to help protect assets, monitor changes in the area and deter crime. The data is accessible through the Knightscope Security Operations Center (KSOC), an intuitive, browser-based interface that enables security professionals to review events generated by the ASRs providing effectively ‘mobile smart eyes and ears’. Learn more at www.knightscope.com/ksoc

The ASRs and the related technologies were developed ground up by the company and are Made in the USA.

The Robot Roadshow

Knightscope has created the ultimate hybrid physical and virtual event, bringing its Autonomous Security Robot technologies to cities across the country for interactive and in-person demonstrations.

Each roadshow landing is hosted virtually by a Knightscope expert, and visitors can interact directly with each of the company’s ASRs and see the Knightscope Security Operations Center (KSOC) user interface in action. Learn more at www.knightscope.com/roadshow

Management Team

Chief Executive Officer William Santana Li is a veteran entrepreneur, a former executive at Ford Motor Company and the founder of GreenLeaf, a company that grew to be the world’s second-largest automotive recycler and is now part of LKQ Corporation (NASDAQ: LKQ).

Chief Client Officer Stacy Dean Stephens brings his experience as a former Dallas law enforcement officer, as well as his skills as a seasoned entrepreneur, to assist on the client acquisition side.

Chief Intelligence Officer Mercedes Soria is an award-winning technologist and former Deloitte software engineer.

Chief Design Officer Aaron Lehnhardt brings over two decades of two- and three-dimensional product and industrial design in modeling and VR to the table, on top of his experience as a senior designer at Ford Motor Company.

Chief Financial Officer Mallorie Burke is a seasoned financial executive and strategic advisor for both private and publicly traded technology companies with a successful track record of mergers & acquisitions, corporate growth and exit strategies, including public listings.

General Counsel Peter Weinberg leverages 30 years of diverse corporate counsel experience, spanning from startups to well-established companies, private and public. He has significant experience training personnel at all levels in critical areas to improve corporate compliance and productivity.

Knightscope, Inc. (NASDAQ: KSCP), closed Thursday's trading session at $4.13, off by 6.982%, on 148,585 volume. The average volume for the last 3 months is 147,979 and the stock's 52-week low/high is $3.91/$27.50.

Recent News

Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

  • In its most recent oral nicotine study, Lexaria established that DehydraTECH-oral nicotine delivery peaked in bloodstream 10x to 20x faster than controls and peak levels achieved were up to 10x higher than controls
  • Lexaria hopes to evidence in its upcoming human oral nicotine study NIC-H22-1, that processing purified nicotine with DehydraTECH leads to better oral-tissue absorption and reduced negative experiences compared to currently sold brands
  • Lexaria’s DehydraTECH technology works with new and existing drugs, processing them into a final form that increases bioavailability, speeds up onset and improves effectiveness that can allow for smaller doses 
  • The company also recently announced new agreements with tobacco giant Altria for evaluation of some of its powder-based nicotine formulations

Technology innovator Lexaria Bioscience (NASDAQ: LEXX) has developed a drug delivery technology designed to increase bio-absorption, reduce time of onset and mask unwanted tastes of a wide variety of medicines and therapeutics. 

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules.  DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has a collaborative research agreement with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has filed for patent protection for specific delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors (with brand names like Viagra), tobacco and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Thursday's trading session at $2.72, off by 9.6346%, on 45,967 volume. The average volume for the last 3 months is 45,567 and the stock's 52-week low/high is $2.525/$12.50.

Recent News

InMed Pharmaceuticals Inc. (NASDAQ: INM)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals Inc. (NASDAQ: INM).

InMed Pharmaceuticals (NASDAQ: INM) is a leader in the research, development, manufacturing and commercialization of rare cannabinoids. The company today announced that its subsidiary, BayMedica, will be providing rare cannabinoids for use in Radicle Science Inc.’s Radicle Energy rare cannabinoid study to assess the effects of delta-9 (“d-9”) dominant tetrahydrocannabivarin (“THCV”) on energy, focus/attention, appetite and weight/BMI. According to the update, BayMedia will be supplying its highly pure d-9 dominant THCV, formulated into a proprietary lozenge manufactured by Trokie. “We are excited to be part of this groundbreaking study with Trokie and Radicle Science in advance of our commercial launch of d-9 dominant THCV. Radicle Science has been at the forefront of cannabinoid research, providing much needed scientific evidence to validate the effects of cannabinoids, and Trokie is a leader in unique and effective delivery systems for cannabinoids,” said Dr. Shane Johnson, SVP and general manager of BayMedica. “As a company driven by data and science, independent third-party research provides important information as we continue to expand our product portfolio of rare cannabinoids for the health and wellness market. Evidence-based decision making is key to facilitate adoption of rare cannabinoids by consumers, brands and health care providers. This research will advance the understanding of rare cannabinoids, which have been historically under-investigated.” To view the full press release, visit https://ibn.fm/ep0SR

InMed Pharmaceuticals Inc. (NASDAQ: INM) is a global leader in the manufacturing and clinical development of rare cannabinoids. InMed is a clinical stage company developing cannabinoid-based pharmaceutical drug candidates, as well as manufacturing technologies for pharmaceutical-grade rare cannabinoids.

The company is dedicated to delivering new therapeutic alternatives to treat conditions with high unmet medical needs. The company is also developing a proprietary manufacturing technology to produce pharmaceutical-grade rare cannabinoids in the lab and has recently announced an LOI to acquire a leading rare cannabinoid manufacturer.

Research and Technology

There are more than 100 rare cannabinoids found in only trace amounts in the cannabis plant, together making up less than 1% of the plant’s biomass. InMed is initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need. Preclinical studies of CBN demonstrated an excellent safety profile and showed CBN has potential for therapeutic benefit over other cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD).

Evidence suggests there may be great therapeutic potential in rare cannabinoids. Each has a specific chemical structure, and different cannabinoids have been observed to have distinct physiological properties in humans, including therapeutic potential for specific diseases as well as unique safety profiles. CBN is the active pharmaceutical ingredient (API) in InMed’s two lead programs for dermatological and ocular diseases.

InMed’s most advanced compound, INM-755, is a CBN topical cream under clinical development for the treatment of epidermolysis bullosa, a severe genetic skin disorder. To date, INM-755 has been evaluated in two Phase 1 clinical trials in healthy volunteers. InMed has filed Clinical Trial Applications in several countries as part of a global Phase 2 clinical trial of INM-755 (cannabinol) cream in epidermolysis bullosa. Responses from the National Competent Authorities and Ethics Committees are expected throughout the summer of 2021.

InMed is also involved in developing INM-088, an ocular CBN formulation being researched for the treatment of glaucoma, the second leading cause of blindness in the developed world. InMed is currently evaluating several formulations to deliver CBN into the eye to address issues of dosing frequency, side effects and treatment penetration. INM-088 is being designed for topical delivery to the eye. This localized delivery results in very little drug being absorbed or migrating into the bloodstream, thus minimizing potential adverse side effects. INM-088 shows promise to reduce intraocular pressure and provide neuroprotection of the eye.

Manufacturing

The limited availability of rare cannabinoids like CBN makes them economically impractical to extract directly from the plant for pharmaceutical use. InMed is developing IntegraSyn, a cannabinoid synthesis manufacturing system to create rare cannabinoids in the lab that are bioidentical to the compounds derived from the cannabis plant. IntegraSyn uses multiple standard pharmaceutical processes and has achieved a cannabinoid yield of 5 grams per liter, surpassing commercial viability and significantly exceeding currently reported industry yields. InMed is now focusing on manufacturing scale-up to larger batch sizes while continuing process optimization, targeting increased cannabinoid yield and further reducing overall cost of goods.

BayMedica Inc. Acquisition

On June 29, 2021, InMed announced it had entered into a non-binding letter of intent to acquire BayMedica Inc., a private company based in Nevada and California that specializes in the manufacture and commercialization of rare cannabinoids.

As noted in the news release, BayMedica is a revenue-stage biotechnology company leveraging its significant expertise in synthetic biology and pharmaceutical chemistry to develop efficient, scalable and proprietary manufacturing approaches to produce high quality, regulatory-compliant rare cannabinoids for consumer applications. BayMedica is currently commercializing the rare cannabinoid CBC (cannabichromene) as a B2B supplier to distributors and manufacturers marketing products in the health and wellness sector. BayMedica is planning additional rare cannabinoid launches for the coming year.

Pursuant to the indicative terms of the LOI, InMed and BayMedica intend to negotiate and enter into a definitive agreement under which InMed would acquire 100% of BayMedica in exchange for 1.6 million InMed common shares to be issued to BayMedica’s equity and convertible debt holders, with any such issued InMed common shares being subject to a six-month contractual hold period.

Market Outlook

There is a rapidly growing demand for rare cannabinoids. However, their low natural concentration makes traditional harvesting of these compounds cost prohibitive. Biosynthesis allows production of rare cannabinoids in the lab that are bioidentical to compounds found in nature, with significantly higher yields which reduce costs. Biosynthesis can produce pharmaceutical-grade, bioidentical, THC-free compounds at a cost that’s 70 to 90 percent less than wholesale prices of naturally harvested rare cannabinoids.

Cannabinoid-based pharmaceuticals are expected to overtake the market as rare cannabinoids become less expensive and more available. According to Statista, the value of the consumer market for cannabinoid-based pharmaceuticals in the United States is forecast to grow to $25 billion by 2025 and to $50 billion by 2029, with cannabinoid-based pharmaceuticals used to treat health conditions including pain, respiratory conditions, autoimmune conditions and more.

Management Team

Eric A. Adams has been CEO and president of InMed since June 2016. He has more than 25 years of experience in establishing corporate entities, capital formation, global market development, mergers and acquisitions, licensing and corporate governance. He previously served as CEO at enGene Inc. Prior to enGene, he held senior positions in global market development with QLT Inc. (Vancouver), Advanced Tissue Sciences Inc. (La Jolla, CA), Abbott Laboratories (Chicago, IL) and Fresenius AG (Germany).

Bruce S. Colwill is InMed’s CFO. He has more than 25 years of financial leadership experience in public and private companies. Prior to InMed, he served as CFO of General Fusion Inc., a private clean energy company. He was also CFO at Entrée Resources Inc., a mineral exploration company, from 2011 to 2016. He has held CFO roles at Neuromed Pharmaceuticals Ltd., Response Biomedical Corp, Forbes Medi-Tech Inc. and Euronet Worldwide Inc.

Alexandra D.J. Mancini is Senior Vice President, Clinical and Regulatory Affairs at InMed. She has more than 30 years of global biopharmaceutical research and development experience. She has been an executive with numerous biotech companies, including senior vice president of Clinical and Regulatory Affairs at Sirius Genomics; senior vice president of Clinical and Regulatory Affairs at INEX Pharmaceuticals; and vice president of Regulatory Affairs at QLT Inc.

Eric C. Hsu is Senior Vice President, Pre-Clinical Research and Development at InMed. He joined InMed with more than 18 years of scientific leadership experience in the field of gene therapy. He has held various positions within enGene Inc., including vice president of Research and vice president of Scientific Affairs and Operations. He received his Doctorate from the Department of Medical Biophysics at the University of Toronto.

Michael Woudenberg is Vice President, Chemistry, Manufacturing and Controls at InMed. He has more than 20 years of successful drug development, process engineering, GMP manufacturing and leadership experience. He has held positions with 3M, Cardiome Pharma, Arbutus Biopharma and, most recently, was Managing Director of Phyton Biotech LLC.

InMed Pharmaceuticals Inc. (INM), closed Thursday's trading session at $0.893, off by 8.3633%, on 146,831 volume. The average volume for the last 3 months is 145,274 and the stock's 52-week low/high is $0.6521/$3.74.

Recent News

Eat Well Investment Group Inc. (CSE: EWG) (OTC: EWGFF)

The QualityStocks Daily Newsletter would like to spotlight Eat Well Investment Group Inc. (CSE: EWG) (OTC: EWGFF).

Eat Well Investment Group (CSE: EWG) (OTC: EWGFF) CEO Marc Aneed, in a recent business letter, acknowledged how the ongoing COVID-19 pandemic, along with the Russia-Ukraine war, had taken a toll on supply chains but expressed utmost confidence in the company’s teams and partners. “Since its inception in 2020, Eat Well Investment Group has managed to deal with one challenge after another, always coming out on top. This has been evidenced by the company’s uninterrupted expansion moves that have seen the acquisition of Belle Pulses Ltd., Sapientia Technology Inc. and Amara Organic Foods. It is also demonstrated by its accelerated distribution plan that has seen mainstream suppliers such as Costco, Walmart and HEB grocery stores stocking its products,” a recent article reads. “Over the 2022 calendar year, the company seeks to execute significant investments and add key team members to expand its physical presence and bolster its functional experience in critical areas. ‘While we successfully executed three major acquisitions within a short time in 2021, we will be making further selective investments and acquisitions to expand each of our portfolio companies’ business reach and adding team members to bolster our functional experience in critical areas,’ noted Mr. Aneed.” To view the full article, visit https://ibn.fm/7TIop

Eat Well Investment Group Inc. (CSE: EWG) (OTC: EWGFF), headquartered in Vancouver, British Columbia, is a publicly traded vertically integrated plant-based foods company combining the best of agribusiness, foodtech, and CPG brands to supply the world with innovative, delicious, and better-for-you foods. The company supplies Beyond Meat, Ingredion, Nestle, General Mills and more. It is on track to generate $60 million in revenue for 2021 and is projecting $100 million in revenue for 2022.

Eat Well’s management team has an extensive record of sourcing, financing and building successful companies across a broad range of industries and maintains a current investment mandate on the health and wellness industry. The team has financed and invested in early-stage venture companies for more than 25 years, resulting in the ability to construct a portfolio of opportunistic investments intended to generate superior risk-adjusted returns. Eat Well’s strategic advisory board includes pioneers in the plant-based foods industry, including HRH Prince Khaled bin Alwaleed bin Talal Al Saud, Founder and Chief Executive Officer of KBW Ventures, and Jeff Dunn, CEO of Bolthouse Farms who previously held senior leadership positions at both Campbell Soup Company and The Coca Cola Company.

The company’s plant-based investment thesis is centered on growing its seed-to-market operations, which include raw ingredients, processing, pulse fractionation, unique IP and premium consumer packaged goods (CPG). Eat Well Group is building a unique ecosystem that can supply these essential cornerstone needs for society. The company has plant-based foods and nutrition experts specializing in the latest science and original thinking for what consumers want most – high quality and affordability in healthy, clean and simple products.

Eat Well focuses on intellectual property, product portfolio development and long-term value creation for stakeholders in a rapidly expanding industry. As an emergent sector globally, plant-based foods represent a double-digit annual growth category, with more than 35% of the world’s supply of pulse proteins coming from Canada.

Portfolio

On July 31, 2021, Eat Well Group acquired Belle Pulses Ltd., one of the top pulse processors in Canada. Belle Pulses has been operating for over 40 years and had over $60 million in sales in 2020. The company counts a broad range of customers in over 35 countries, including global strategic food companies and major ingredient distributors. Currently, Belle produces nearly 100,000 tons of fully traceable seed and product, yielding over 26,000 tons of pure plant protein.

Eat Well also owns 100% of Sapientia Technology Inc. Led by Dr. Eugenio Bortone – one of the world’s preeminent food scientists and extrusion processing experts and the inventor of Frito-Lay’s Twisted Cheetos – Sapientia has filed four patents around the “protein curl” and crispy-puff-style snack. By focusing on texture and crunch, Sapientia’s patents solve one of the major problems that large scale snack food companies have struggled with for years – how to offer appealing texture and flavor in a guilt-free, not fried, natural and healthy alternative to the majority of snack food products available today.

Eat Well owns a 51% share of Amara Organic Foods, with an option to acquire additional ownership up to 80 percent. Amara, one of the fastest-growing baby food brands in America, is a food technology company that uses science and proprietary IP that locks in taste and texture to make healthy, organic, non-GMO, plant-based, convenient baby and children’s food possible for modern-day families. From baby food to toddler food and beyond, Amara is driven by the belief that setting kids on the right path from a young age will help them live better, feel better and think better for the rest of their lives. Amara’s revenues have grown by more than 400% since January 2021, and the brand’s success has drawn media coverage from business news outlets including Forbes and TechCrunch.

Market Outlook

According to an August 2021 report from Bloomberg Intelligence, the plant-based foods market is expected to experience explosive growth, comprising up to 7.7% of the global protein market by 2030 at a value of over $162 billion, up from $29.4 billion in 2020. Bloomberg notes that plant-based alternatives are here to stay, and that consumption will grow rapidly. Plant-based food sales in 2020 grew twice as fast as overall food sales, according to Polaris Market Research.

Pulse proteins (fava, yellow pea, etc.) are a foundational ingredient to most plant-based foods due to their high protein content and their readily available, affordable supply.

Many analysts view the food tech market as similar to the early days of the Internet in that plant-based foods represent a worldwide secular trend of steady growth and potential that will revolutionize the way society functions and people experience nutrition.

The sector continues to experience significant M&A transactions. Recently, Sol Cuisine was acquired by PlantPlus Foods LLC, a major South American protein producer, in an all-cash transaction valued at approximately $126 million, or 6x revenue.

Management Team

Marc Aneed is President and Director of Eat Well Group. His 20-year career in CPG started at The Quaker Oats Company/PepsiCo, where he worked on iconic brands like Gatorade. He previously was at Glanbia PLC, a global nutrition company, where he led Amazing Grass, a leading plant nutrition and supplement company with over $100 million in retail sales. He also led Glanbia’s Sports Nutrition brands in North America with over $750 million in retail sales. Mr. Aneed has launched dozens of successful consumer products, driving over $1 billion in collective retail sales.

Mark Coles is the company’s Chief Investment Officer. He is a veteran CPG senior executive specializing in the plant-based foods sector. For the past decade, Mr. Coles has spearheaded global plant-based start-up initiatives, culminating in a 2020 acquisition by an international New York Stock Exchange-listed food ingredient company. He has over 25 years of experience in CPG-focused strategy, mergers and acquisitions and project financing.

Patrick Dunn is Eat Well Group’s Vice President, Finance. He is the founding partner of Dunn, Pariser & Peyrot and has a track record of building highly successful agribusinesses throughout North America and other international markets. As a testimony to his business portfolio work, Mr. Dunn and his firm have won multiple industry awards for accounting, finance and business management.

Barry Didato is the company’s Vice President, Strategy. He is focused on the development of strategic revenue channels, sales partnerships, and international distribution for Eat Well Group. Mr. Didato brings extensive strategic sales capabilities and an extensive network of contacts in the industry to the company. Prior to joining Eat Well Group, he served for over 18 years as a senior advisor for several ultra-high net worth family offices and numerous innovative wellness, nutrition, medical, and food businesses.

Strategic Advisory Board

HRH Prince Khaled bin Alwaleed bin Talal Al Saud, Founder and Chief Executive Officer of KBW Ventures, is a firm supporter of clean energy and the humane treatment of animals. He is also a vocal supporter of the private sector in the Middle East. A member of the Saudi Arabian Royal Family, Prince Khaled was born in Stanford and spent his youth in Riyadh under the mentorship of his father, philanthropist HRH Prince Alwaleed bin Talal Al Saud, Chairman of Kingdom Holding Company. He is also the Founding Chairman of KBW Investments and serves across several boards. He invests in an array of successful but diverse global businesses – from promising technology startups to established companies. Today, with holdings on three continents, Prince Khaled stands at the gateway between the Middle East’s evolving economies and the Western world. Consistently, Prince Khaled’s focus is on ventures and ideas at the intersection of innovation and economic growth.

Jeff Dunn has over 30 years of experience in agriculture and packaged food, including senior leadership positions with Bolthouse Farms, Campbell Soup Company and The Coca Cola Company, among others. He is an Operating Partner at Butterfly and focuses primarily on the agriculture & aquaculture and food & beverage product sectors. Prior to joining Butterfly, Mr. Dunn was the President of the Campbell Fresh division of Campbell Soup Company from 2015 to 2016, where he was in charge of building Campbell’s scale and accelerating its growth in the rapidly expanding packaged fresh segments and categories across the retail perimeter.

Eat Well Investment Group Inc. (OTC: EWGFF), closed Thursday's trading session at $0.23805, off by 5.1934%, on 41,648 volume. The average volume for the last 3 months is 41,648 and the stock's 52-week low/high is $0.23805/$1.00.

Recent News

Silo Pharma Inc. (OTCQB: SILO)

The QualityStocks Daily Newsletter would like to spotlight Silo Pharma Inc. (OTCQB: SILO).

A new study has provided new insights into why the SARS-CoV-2 virus, which is known to cause COVID-19, can sometimes fuels inflammation, which in turn causes serious illness. This research was led by scientists at Boston Children’s Hospital and Harvard Medical School. Its findings were published in the “Nature” journal.

Silo Pharma Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company, is focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as post-traumatic stress disorder (PTSD), fibromyalgia, Alzheimer’s disease, Parkinson’s disease, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund research that the company believes will be transformative to the wellbeing of patients and the health care industry.

Silo is committed to developing innovative solutions to address a variety of underserved conditions. Combining Silo’s resources with world-class medical research partners, the company looks to make significant advances in the medical and psychedelic space.

Silo works to identify and partner with leading medical universities, providing the needed financial resources to develop safe therapeutic treatments while moving cutting-edge research through the clinical stage and into commercialization. The company is well-capitalized with access to additional funds as opportunities present themselves.

Silo recently engaged Donohoe Advisory Associates LLC for consulting and advisory services in connection with the potential uplisting of Silo’s common shares to the Nasdaq Stock Market.

Research

Silo has entered into research agreements and partnerships with multiple leading medical universities.

The company is involved in a sponsored study with Maastricht University utilizing repeated low doses of ketamine and psilocybin to examine the effects on cognitive and emotional dysfunctions in Parkinson’s disease and to understand its mechanism of action. The investigator in the Netherlands is acquiring the substances for the study and will then finalize the documentation to submit to the ethics committee.

Additionally, in June 2021, Silo announced its entry into a scientific research agreement with the University of California San Francisco (UCSF). The agreement will leverage four other clinical trials being planned by the university to determine the effects of psilocybin on inflammation. The study will take place at The Translational Psychedelic Research (TrPR) Program at UCSF.

Silo also recently extended its exclusive option agreement with the University of Maryland, Baltimore (UMB) to explore a novel invention generally known as joint-homing peptides. These peptides are being developed for use in the investigation and treatment of arthritogenic processes and can be used for enhanced targeting of therapeutic agents.

This agreement includes the study of two separate peptides. The first is an option and study for the treatment of arthritis. The second is a patented licensed peptide for the central nervous system, with an initial study for MS autoimmune diseases, in addition to rheumatoid arthritis. Animal studies are underway for both initial indications relating to the UMB agreement, with the potential for studies evaluating additional indications in the future.

Finally, Silo signed an agreement with Columbia University granting it an option to license certain assets currently under development, including an Alzheimer’s disease formulation targeting NDMARs and 5-HT4Rs, as well as a prophylactic treatment for stress-induced disorders and PTSD. Both candidates are currently being tested in mice and have already provided early data.

In addition to its university partnerships, Silo entered a joint venture agreement with Zylo Therapeutics Inc. (“ZTI”) focused on the development of ketamine and psilocybin using ZTI’s Z-Pod™ technology for the transdermal time released delivery of therapeutics. In November 2021, the company announced ZTI’s reception of its first ketamine shipment and initiation of loading ketamine into its Z-Pod technology. In a news release, Eric Weisblum, CEO of Silo, called the development an “important milestone” that will help the company “study the benefits of slow-release transdermal release of Ketamine.”

Market Overview

According to Coherent Market Insights, the fibromyalgia treatment market was valued at $2.78 billion in 2018 and has a projected CAGR of 3.3% over the forecast period 2018 to 2026. Fibromyalgia is a condition that causes pain all over the body, sleep problems, fatigue, and emotional and mental distress.

The global PTSD therapeutics market is expected to reach $10.68 billion by 2026 with a CAGR of 4.5% during the forecast period from 2018 to 2026, according to a report by Credence Research. Growing prevalence of PTSD is the chief factor driving the global treatment market. Increases in events such as wars, combat, and interpersonal violence has been a major contributing factor. Other factors like growing emphasis on rehabilitation initiatives by governments for treating their war veterans has also been facilitating the increase in demand for PTSD therapeutics.

Fortune Business Insights reports the global Parkinson’s disease treatment market is predicted to grow to $8.38 billion by 2026, with a CAGR of 8.1% during the forecast period. Parkinson’s is a neurodegenerative disease of the central nervous system which primarily affects the brain, causing uncontrollable shaking and tremors, difficulties in balance and restricted body movement making it difficult for the person to function or perform a daily routine.

Management Team

Eric Weisblum is CEO and founder of Silo Pharma. He has over 25 years of Wall Street experience, most recently in the biotechnology sector. He has served on the board of Aikido Pharma and was the president of Sableridge Capital. He has a proven track record in licensing therapeutic assets and assisting in their development. He brings to the company nearly 20 years of expertise in structuring and trading financial instruments. He holds a bachelor’s degree from the University of Hartford’s Barney School of Business.

Dr. Kevin Muñoz was appointed to the Silo board of directors in October 2020. He teaches biomedical sciences and medical intervention for the Passaic County Technical Institute. He previously served as Director of Operations at Physical Medicine and Rehabilitation. He began his career with Harlem Health Promotion Center in New York City as a research assistant. He earned a bachelor’s degree from the University of Michigan and a Doctor of Medicine from Xavier University School of Medicine.

Josh Woolley, M.D., Ph.D., is a Scientific Advisor for Silo. He is an associate professor in the Department of Psychiatry and Behavioral Sciences at the University of California, San Francisco. He is also a psychiatrist on staff at the San Francisco Veterans Affairs Medical Center. He is the director and founder of the Bonding and Attunement in Neuropsychiatric Disorders Laboratory. He received both his M.D. and his Ph.D. in Neuroscience from UCSF, where he completed his psychiatry residency training.

Charles Nemeroff, M.D., Ph.D., is a Scientific Advisor for Silo Pharma. He directs the Institute for Early Life Adversity Research within the Department of Psychiatry and Behavioral Sciences as part of the Mulva Clinic for the Neurosciences. He was chair of the Department of Psychiatry and Behavioral Sciences and clinical director of the Center on Aging at the University of Miami Miller School of Medicine. He received his M.D. and Ph.D. in neurobiology from the University of North Carolina School of Medicine.

Silo Pharma Inc. (OTCQB: SILO), closed Thursday's trading session at $0.1627, off by 2.2823%, on 40,682 volume. The average volume for the last 3 months is 40,682 and the stock's 52-week low/high is $0.12/$0.31.

Recent News

Laredo Oil Inc. (OTC: LRDC)

The QualityStocks Daily Newsletter would like to spotlight Laredo Oil Inc. (LRDC).

  • LRDC Exec Mark See discussed management, focus and strategy during recent podcast interview
  • Short supply, increasing demand means simple business plan
  • Laredo is acquiring assets that are “smaller but meaningful,” says CEO

Laredo Oil (OTC: LRDC) chair and CEO Mark See was the featured guest in a recent Bell2Bell Podcast (https://ibn.fm/2e8xL). A seasoned veteran of the oil and gas sector, See talked shop with host Stuart Smith throughout the interview, discussing Laredo management, focus and strategy. 

Laredo Oil Inc. (OTC: LRDC) is a publicly traded oil and gas exploration and production (E&P) company engaging in the acquisition and development of both undervalued quality conventional oil and gas properties and select mature oil fields that are suitable for the company’s proprietary Enhanced Oil Recovery (EOR) methods.

Laredo Oil is headquartered in Austin, Texas.

Conventional Acreage

Laredo Oil’s primary focus is on acquiring, developing, and operating undervalued conventional oil and gas properties.

The company leased 23,739 mineral acres in the Western Williston Basin of Montana, at favorable prices during the most recent down cycle and continues to take leases in the area. Before year end, it expects to drill the first development well at one of the first of 10 potential locations it has identified. If that well yields the anticipated results, the company plans to begin drilling additional wells there as soon as practical thereafter. The company believes the leased acreage has the potential to yield at least five years of development opportunities.

The company intends to pursue aggressively the acquisition of quality assets that major, mid-major, and large independent oil and gas companies continue to divest themselves of at a discount in response to ESG (Environmental, Social and Governmental) & sustainability initiatives and other pressures imposed upon them by their activist boards of directors. The company will focus on value, growth potential and free cash flow while complying with common sense ESG policies, often having a lower environmental impact than its competitors through its EOR methods.

EOR

In addition to pursuing conventional acreage and properties, Laredo Oil plans to acquire additional select mature oil fields where it believes that it can profitably use its proprietary Underground Gravity Drainage™ (UGD) model to recover stranded oil reserves (reserves previously considered to be economically incapable of recovery). The UGD method is applicable to mature oil fields that have very specific geological and reservoir characteristics.

Laredo Oil has done extensive research and field level application over the last 10 years and has identified specific oil fields within the United States that it believes are qualified for the UGD recovery method. The company believes the costs of implementing the UGD method are significantly lower than those of other commonly used EOR methods. Laredo Oil believes that it can materially increase the field oil production rate from prior periods and, in some cases, recover amounts of oil equal to or greater than amounts previously recovered from the mature fields selected.

Market Outlook

The company expects U.S. oil prices to climb in the near term as energy demand intensifies with the economy continuing to recover from the COVID-19 slowdown. Also causing upward price pressure is global supply chain dysfunction that slows or prevents shipments, including energy components, from reaching destinations. Domestic oil production is also constrained by years of reduced investment in fossil fuel producers due to green energy mandates. Accordingly, the company believes that the short-term outlook for oil is favorable. Many industries have yet to reach their pre-COVID production levels, which the company believes points to a continuing near-term upward trend in energy demand.

Management Team

Mark See has been the Chief Executive Officer and Chairman of the Board of Directors of the company since October 16, 2009. He has over 30 years’ experience in heavy civil, natural resources and the E&P industries. He was the founder and founding CEO of Rock Well Petroleum, a private oil & gas company until December 2008 and worked from then until October 2009 forming Laredo Oil. He was employed with Albian Sands as the Manager for the Alberta Oil Sands Projects at Fort McMurray, Alberta, Canada, a joint venture between Shell Canada and Chevron. Mr. See was also President of Oil Recovery Enhancement LLC in Bozeman, Montana, a private oil company. He was selected as one of the top 25 Engineers in North America by the Engineering News Record for his innovations in the petroleum industry. He is a graduate of the Mackay School of Mines at the University of Nevada at Reno, with a degree in Mining Engineering. He is a member of the Society of Mining Engineers and the Society of Petroleum Engineers.

Bradley Sparks currently serves as the Chief Financial Officer and Treasurer of Laredo Oil and has been a director of the company since March 1, 2011. Before joining Laredo Oil in October 2009, he was the Chief Executive Officer, President and a Director of Visualant Inc. Prior to joining Visualant, he was the Chief Financial Officer of WatchGuard Technologies Inc. from 2005-2006. Before joining WatchGuard, he was the founder and managing director of Sunburst Growth Ventures LLC, a private investment firm specializing in emerging-growth companies. Previously, he founded Pointer Communications and served as Chief Financial Officer for several telecommunications and internet companies, including eSpire Communications Inc., Digex Inc., Omnipoint Corporation, and WAM!NET. He also served as Vice President and Treasurer of MCI Communications from 1988-1993 and as Vice President and Controller from 1993-1995. Before his tenure at MCI, Mr. Sparks held various financial management positions at Ryder System Inc. He currently serves on the Board of Directors of Comrise. Mr. Sparks graduated from the United States Military Academy at West Point in 1969 and is a former Army Captain in the Signal Corps. He has a Master of Science in Management from the Sloan School of Management at the Massachusetts Institute of Technology and is a licensed CPA in Florida.

Donald Beckham has served as a director of the company since March 1, 2011. Since July 2015, he has been a partner with Copestone Energy Partners LLC. In 1993, he founded Beckham Resources Inc. (“BRI”), which, for over 30 years, has been a licensed, bonded and insured operator in good standing with the Railroad Commission of Texas. Through BRI, Mr. Beckham has drilled and operated fields for his own account. His expertise is in the acquisition, exploitation, exploration and production enhancement of mature oil and gas fields through which he has been able to enhance production by compressor optimization, pump design, work-over programs, stimulation techniques and identifying new pay zones. Prior to BRI, Mr. Beckham was the chief operations manager for Houston Oil Fields Corporation (“HOFCO”), where he began his career. There, he was responsible for drilling, production and field operations and managed approximately 100 people, including engineers, geologists, land men, pumpers, and other contract personnel, as well as state and federal environmental and regulatory functions. He managed an annual capital budget of approximately $30 million and operated approximately 100 wells. HOFCO drilled about 20 wells per annum and performed approximately 30 recompletions and work over operations each year. HOFCO owned interests in about 10 key fields principally in Texas, and company-managed production was approximately 1,000 bpd of crude oil and 10 mm cfd of natural gas. Mr. Beckham is a petroleum engineer and 1984 graduate of Mississippi State University.

Michael Price, an independent director of Laredo Oil, has over 40 years of senior financial and petroleum experience in the global oil and gas industry. He has been a principal in Octagon Energy Advisors, a Houston-based energy investment advisory firm, from 2002 to the present. The firm advises financial institutions and institutional investors participating in energy investments. From 2008 through his retirement in 2021, he was a Managing Director at ING Capital, which provides debt financing to domestic exploration and production companies. From 1998 through 2002, Mr. Price was the Chief Financial Officer of Forman Petroleum Corporation. Before that, Mr. Price was Managing Director at Chase Manhattan Bank for 15 years and was in charge of technical support for Chase’s worldwide energy merchant banking activities. In his early career, he worked as a consulting principal on domestic petroleum engineering and landowner matters and gained extensive international experience working with major oil companies in a variety of operating positions. He holds a BS and MS from Illinois Institute of Technology, an MBA from the University of Chicago, a M.Sc. from the London School of Economics, and an MS in Petroleum Engineering from Tulane University.

FORWARD-LOOKING STATEMENTS

This press release and the statements made by Laredo Oil, Inc. in this press release may be forward-looking in nature and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements describe Laredo Oil’s future plans, projections, strategies and expectations, and may be identified by words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “seeks”, “estimates” or the negative versions of those words or other words of similar meaning. These forward-looking statements are based on assumptions and involve a number of risks, uncertainties, situations and other factors that may cause the actual results, level of activity, performance or achievements of Laredo Oil or the oil industry to be materially different from any future results, level of activity, performance or achievements expressed or implied by these statements. These factors include changes in interest rates, market competition, changes in the local and national economies, and various other factors detailed from time to time in the reports filed with, or furnished to, the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Laredo Oil undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events.

Laredo Oil Inc. (LRDC), closed Thursday's trading session at $0.095, off by 13.6364%, on 42,535 volume. The average volume for the last 3 months is 42,535 and the stock's 52-week low/high is $0.0401/$0.2714.

Recent News

Cannabis Strategic Ventures Inc. (OTC: NUGS)

The QualityStocks Daily Newsletter would like to spotlight Cannabis Strategic Ventures Inc. (NUGS).

While marijuana has been in existence for centuries, it is still a controversial plant. The U.S. federal government classifies it under Schedule 1 of the Controlled Substances Act alongside hard drugs such as meth and cocaine despite the DEA admitting in 2020 that no cannabis overdose has ever been recorded. An estimated 55 million people in the U.S. use marijuana, and many more states continue to enact marijuana laws either through legislative means or through ballot measures. So how has the use of this substance evolved in the course of the COVID-19 pandemic? As the pandemic goes on, we may see new developments in the way people use the cannabis products made by companies such as Cannabis Strategic Ventures Inc. (OTC: NUGS) either for medical or recreational purposes.

Cannabis Strategic Ventures Inc. (OTC: NUGS) is an emerging leader in the U.S. cannabis marketplace as a publicly traded cannabis cultivator. The company is based in Los Angeles, with a 6-acre cannabis farm in Northern California called NUGS Farm North. The company’s vision is to acquire and scale assets in the legal cannabis market while achieving efficiencies through economies of scale and vertical integration.

Cannabis Strategic Ventures recently expanded its portfolio by completing the transfer process for cultivation, retail, distribution and manufacturing licenses issued by the City of Los Angeles and the State of California, and it is now working toward taking operational control of each license. The company also recently announced the upcoming grand opening of its cannabis dispensary, MDRN Tree. Following that launch, Cannabis Strategic Ventures intends to deploy another of its new licenses to establish an indoor cultivation facility with capacity to produce two to three pounds of premium exotic cannabis flower per light per harvest. The facility will have up to 1,200 grow lights and is anticipated to yield 5.75 harvests per year, bringing it to a total production capacity of over 15,000 pounds of cannabis flower annually.

Brand Portfolio

The company owns multiple brands under the Cannabis Strategic Ventures umbrella. The firm’s NUGS brand provides operational and financial strategic partnerships and a range of essential services to emerging and existing cannabis consumer brands.

The NUGS Farm North brand operates as a six-and-a-half-acre cannabis cultivation property located in northern California. The company believes that the key to success in its business is consistent quality and reliable supply to fit growing consumer demand. Cannabis Strategic Ventures addressed these consumer needs by building NUGS Farm North. At NUGS Farm North, the company’s process is customized, and its product is consistent. Located in the heart of an agricultural mecca for globally distributed produce, NUGS Farm North finds power in its product, not in its size. Decades of agricultural experience and a dedication to consistency ensure quality cannabis.

MDRN Tree is Cannabis Strategic Ventures’ customer-facing dispensary brand. MDRN Tree will open its first Los Angeles location sometime in the fall of 2021. MDRN Tree will be the company’s factory retail store – a direct interface with the end-market community – where Cannabis Strategic Ventures plans on showcasing the cannabis flower produced at its NUGS Farm North cultivation site. This farm-to-sale model offers the potential to drive simultaneous gains in quality control and profitability.

Market Outlook

The demand for legal marijuana is expected to surge due to ongoing changes in U.S. state government policies toward cannabis. In addition, the number of indications for which medical marijuana is prescribed continues to increase steadily. These factors are expected to rapidly boost legal sales of cannabis products, opening new revenue channels for producers and retailers. Furthermore, an anticipated federal legalization of medical marijuana in the U.S. will only present more high growth opportunities for this market.

According to a report from Grand View Research, the global legal marijuana market was valued at $9.1 billion in 2020. Market size is forecast to grow at a compound annual growth rate of 26.7 percent from 2021 to 2028. That CAGR would put the market value at roughly $30 billion as soon as 2025.

According to the report, “One of the major factors fueling market growth is the expanding demand for legal marijuana owing to the growing number of legal cannabis countries. (Due) to recent legalizations in different countries, the use of medical marijuana for various ailments is gaining momentum worldwide. Patients suffering from chronic illnesses such as Parkinson’s, cancer, Alzheimer’s, and many neurological disorders are administered medical marijuana. The demand for cannabis oil is increasing rapidly, especially among countries with legalized medical marijuana.”

Management Team

Simon Yu is CEO, President, CFO and Secretary of Cannabis Strategic Ventures. He is also a co-founder, former COO and board member of Clubhouse Media Group Inc., a publicly traded social media company. Mr. Yu holds an MBA from the University of Southern California.

Cannabis Strategic Ventures Inc. (NUGS), closed Thursday's trading session at $0.021, off by 5.8296%, on 799,077 volume. The average volume for the last 3 months is 799,077 and the stock's 52-week low/high is $0.014794/$0.10.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.